FINITE ELEMENT ANALYSIS OF CANCELLOUS BONE by Wilkerson, Lucas T
University of Kentucky 
UKnowledge 
Theses and Dissertations--Mechanical 
Engineering Mechanical Engineering 
2012 
FINITE ELEMENT ANALYSIS OF CANCELLOUS BONE 
Lucas T. Wilkerson 
University of Kentucky, lucas.wilkerson@gmail.com 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Wilkerson, Lucas T., "FINITE ELEMENT ANALYSIS OF CANCELLOUS BONE" (2012). Theses and 
Dissertations--Mechanical Engineering. 17. 
https://uknowledge.uky.edu/me_etds/17 
This Master's Thesis is brought to you for free and open access by the Mechanical Engineering at UKnowledge. It has 
been accepted for inclusion in Theses and Dissertations--Mechanical Engineering by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained and attached hereto needed written 
permission statements(s) from the owner(s) of each third-party copyrighted matter to be 
included in my work, allowing electronic distribution (if such use is not permitted by the fair use 
doctrine). 
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive 
and make accessible my work in whole or in part in all forms of media, now or hereafter known. 
I agree that the document mentioned above may be made available immediately for worldwide 
access unless a preapproved embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s dissertation 
including all changes required by the advisory committee. The undersigned agree to abide by 
the statements above. 
Lucas T. Wilkerson, Student 
Dr. Keith Rouch, Major Professor 
Dr. James McDonough, Director of Graduate Studies 
 
 
 
 
 
 
 
 
 FINITE ELEMENT ANALYSIS OF CANCELLOUS BONE 
 
 
 
 
 
THESIS 
 
 
A thesis submitted in partial fulfillment of the requirements for 
the degree of Master of Science in Mechanical Engineering in  
the College of Engineering at the University of Kentucky 
 
 
 
By 
 
Lucas T. Wilkerson 
 
Lexington, Kentucky 
 
Co-Directors: Dr. Keith Rouch, Professor of Mechanical Engineering  
And        Dr. David Pienkowski, Professor of Biomedical Engineering 
 
Lexington, KY 
 
2012 
 
Copyright © Lucas T. Wilkerson 2012 
 
 
 
 
 
 
 
 
 ABSTRACT OF THESIS     FINITE ELEMENT ANALYSIS OF CANCELLOUS BONE 
 
A variety of pathologies exist which increase the likelihood of bone fracture.  Present methods 
for determining the fracture risk of a specific patient are based exclusively on the amount of 
bone present.  While the quantity of bone tissue is correlated with strength, it neglects to 
account for bone’s intricate microarchitecture.  To assess the effect of bone quality on strength, 
a methodology was developed for the structural analysis of cancellous bone biopsies.  Thirty 
biopsies were selected from a pre-existing biopsy bank, and scanned using a SCANCO µCT-40 at 
a resolution of 30 microns.  Cortical bone was removed from the resulting three-dimensional 
geometry, and the remaining cancellous bone was meshed with solid tetrahedral elements.  A 
linear static uniaxial compression test was performed using ANSYS v14.0 to determine the 
apparent-level Young’s modulus.  The maximum von Mises stress was also investigated, but 
showed poor convergence with increased mesh density.  Consistent with the methodology of 
Pistoia et al., the failure load was assumed to occur when 2% of the bone volume exceeded 
7000 µstrain.  The results of the finite element analysis compared favorably with known values 
for cancellous bone strength.    
KEYWORDS: Finite Element Method, MicroCT, Human Iliac Bone, Bone Strength, Bone Stiffness 
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1 Introduction 1.1 Prevalence of Osteoporosis 
Osteoporosis is a bone disease characterized by decreased bone mineral density and increased 
fracture rates.  The disease is most prevalent in post-menopausal Caucasian women, but it is 
present in all ethnicities and age levels.  According to the National Osteoporosis Foundation, 
50% of women, and up to 25% of men over age 50 will experience an osteoporosis-induced 
fracture [1].  By 2020, it is estimated that osteoporosis will affect 14 million Americans [2].  With 
the number of Americans over the age of 65 expected to double from 2010 to 2040 [3], 
osteoporosis will become an ever more pressing medical problem.   
There is no single treatment for osteoporosis.  The condition can be prevented and abated by 
proper intake of calcium and vitamin D [4], and by physical activities which safely increase bone 
loading [5,6].  However, for advanced cases of osteoporosis, medication is the de facto course of 
action.  Hormone replacement therapy, raloxifene, teriparatide, calcitonin, denosumab, and 
bisphosphonates are all used to combat osteoporosis.  Of all of the treatment options, 
bisphosphonates are the most often prescribed solution [7].  From May 2003 to April 2004, 22 
million prescriptions were written for Fosamax (a specific bisphosphonate) alone [8].  1.2 Research Objectives 
The high-order objective of this research is to reduce the rate of bone fractures in patients 
suffering from osteoporosis.  As with most non-trivial problems, there are a myriad of ways one 
may attempt to accomplish the objective.  Time could be devoted to creating new medications, 
understanding present therapies, preventing falls, or an untold number of potentially fruitful 
endeavors.  Work is being done to comprehend the physiopathology of osteoporosis [9], the 
role of genetics in susceptibility to osteoporosis [10], and in preventing the falls which are often 
associated with fracture [11].     
In this research, the goal of reducing osteoporotic fractures will be fulfilled by investigating the 
long-term effect of bisphosphonate use on bone strength.  Bisphosphonates function by 
decreasing the resorption of bone.  Initially, bone strength is unarguably increased because the 
net rate of bone formation increases.  However, it has been hypothesized that long term use 
could actually decrease strength due to increased mineralization or accumulation of unrepaired 
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microdamage [12].  Alteration of micro-architecture has also been shown to be an important 
factor in bisphosphonate’s function [13], and it is the main factor investigated in this work. 
If it is shown that long-term bisphosphonate use decreases bone strength, then putting a cap on 
the duration of bisphosphonate use should decrease the number of fractures seen in the 
population.  If, on the other hand, the null hypothesis cannot be rejected, doctors and patients 
can be slightly more comfortable with the extended use of bisphosphonate treatment. 
In order to assess the effect of bisphosphonate use on bone strength, a method is needed to 
determine the failure load of bone tissue.  Currently, dual-energy x-ray absorptiometry (DXA) is 
the standard test for diagnosing osteoporosis.  The test measures bone mineral density (BMD).  
The result of the test is a two dimensional image, with each point representing the x-ray 
attenuation of the corresponding 1-D path through the bone.   DXA cannot compute true 
density, since the bone volume is not known.   Instead, the BMD score is based on the cross 
sectional area of the bone.  Other, more invasive tests are occasionally used to evaluate bone 
strength.  If a biopsy is taken, a smorgasbord of parameters can be collected, all of which play a 
role in bone strength.  In concert with tetracycline double labeling [14], a biopsy can determine 
turnover rate [15], mineralization, collagen cross-linking, trabecular thickness, trabecular 
separation, hardness, young’s modulus, osteoid thickness, and erosion depth.    
Unfortunately, the above methods only measure bone strength indirectly.  What is needed is a 
way to determine the stresses and strains inside the tissue in response to load; only then can a 
failure mechanism be determined.   Thankfully, the mechanics of materials is a well-established 
field, and engineers have been putting the knowledge to good use for decades [16]. So, while 
the objective is rooted in the medical arena, the means to accomplish the goal is well within the 
wheelhouse of mechanical engineering.   
By developing a finite element model to gage the load capability of cancellous bone tissue, the 
true effect of bisphosphonate use can be determined.  Furthermore, the same finite element 
method can be used in future studies.  Ideally, with high-resolution in-vivo scans, the population 
may one day benefit from improved identification of at-risk patients. 
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Figure 1-1: Visualization of Objectives 
                         1.3 Motivation 
The motivation underpinning this research may seem obvious: to save and improve the lives of 
those afflicted with osteoporosis.  However, what may be less apparent is just how devastating 
a fracture is for the typical osteoporotic person.  After fracturing a hip, 17-33% of patients die 
with one year of being discharged from the hospital [17].  (To be fair, not all of the deaths can 
be directly attributed to the fracture [18,19].) Of the patients who survive a hip fracture, less 
than half regain their previous level of independence [20].   
Based on those grave statistics, anything that can be done to reduce the frequency or severity of 
osteoporotic fractures is well worth the effort.  As a purely secondary consideration, preventing 
fractures would not only improve quality of life, but also save the medical system billions of 
dollars.  It is projected, that by 2025, the US will experience more than 3 million osteoporosis-
related fractures per year, at a financial cost of $25.3 billion [1]. While it is crass to put a dollar 
value on human life, there is no denying that there is an opportunity cost for every dollar spent.  
Funds spent repairing bone fractures could instead be spent researching heart disease, 
providing medical treatment to underprivileged children, or engineering advanced surgical 
devices, all of which would likely save lives.     
So, the empathetic motivation has been vividly established, but that alone doesn’t justify 
research.  The technical motivation stems from the fact that none of the widely-used bone 
metrics fully assess the strength of bone.  BMD, for example, has been correlated with fracture 
Reduce Osteoporotic Fractures 
Study Bisphosphonate 
Use 
Assess Individual 
Bone Strength 
Develop  
FEM 
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risk beyond any doubt [21].  However, the relationship between BMD and bone strength on a 
population level does not tell us the bone strength of an individual.  In fact, current research 
already indicates that there is significant room for improvement [22,23].  By looking at the 
microarchitecture of a specific patient’s bone, it should be possible to generate a much more 
accurate estimate of bone strength.   1.4 Study Design 
In order to determine the relationship between duration of bisphosphonate use and cancellous 
bone strength, it is necessary to have bone tissue which has been exposed to the drug for 
varying periods of time.  In an ideal situation, a group of patients who were freshly prescribed 
bisphosphonates would have high-resolution in-vivo bone scans at the hip prior to their first 
dose of bisphosphonates.  Then, periodically, they would be re-scanned for the next decade of 
treatment.  This would eliminate a host of uncontrolled variables, and allow for a more powerful 
paired statistical test.  In addition to being lengthy and expensive, the study described would 
also be impractical with present technology.  In-vivo scanning by peripheral quantitative 
computed tomography (pQCT) is currently limited to scanning at the distal radius and tibia.   
In order to work within the limitations of microCT scanning, research duration, and cost, it was 
decided to perform the study on previously extracted bone biopsies rather than new patients.  
For decades, Dr. Hartmut H. Malluche, MD of the University of Kentucky has been cataloging 
iliac crest biopsies.  The biopsies are embedded in acrylic, preserving them indefinitely.  They 
require no special storage conditions, and are organized using the system depicted in Figure 1-2.  
A typical biopsy is shown in Figure 1-3. 
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Figure 1-2: Biopsies Collected During Year 2005 
 
Figure 1-3: A Representative Biopsy 
 
The total collection has over 8000 biopsies, but this study selected from a much smaller set of 
approximately 700 patients.  The reduction is primarily the result of eliminating biopsies 
extracted prior to 1997. (The FDA approved the use of Fosamax in 1995.)  While the older 
biopsies are still valid for study, they have less detailed documentation and are unlikely to 
contain bisphosphonate patients.  The small subset is also attributable to the fact that only 
osteoporotic patients were considered for study.   
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From the set of 700 osteoporotic biopsies, three sets of 10 groups were chosen.  The first set 
had been diagnosed with osteoporosis, but had not yet taken bisphosphonates.  The second set 
had been using bisphosphonates for one to five years at the time of the biopsy.  Finally, the third 
set had more than 5 years of bisphosphonate use at the time of the biopsy.  
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2 Background 
Due to the interdisciplinary nature of this work, an overview of both the medical aspects and the 
engineering aspects is in order.   In an effort to cater to the widest possible audience, the 
material starts at a fairly basic level.  Those proficient in both disciplines, namely biomedical 
engineers, may wish to skip to the Prior Work section.    2.1 Overview of Bone 2.1.1 Anatomy 
2.1.1.1 Gross Anatomy 
At the macroscopic level, bones are responsible for resisting routine locomotive forces and 
protecting vital soft tissue during traumatic events.  The adult skeleton contains 206 bones, and 
has a dry fat-free mass 6-7% of total body mass [24].  Bones are classified into 5 categories 
based on their shape: long, short, flat, sesamoid, and irregular.  Long bones, such as the 
humerus, are further subdivided into epiphyseal bone at the ends, and diaphyseal bone along 
the central portion (Figure 2-1).  The carpals, connecting the hand and forearm, are short bones.  
They have no one dimension that dominates the others.  The biopsy location in this study, the 
ilium, is categorized as a flat bone.   Flat bones generally offer protection, or an expansive site 
for muscular attachment.   Sesamoid bones protect tendons that have to span over joints.  
Finally, the irregular classification is nothing but a catch-all for the misfits, like vertebrae.     
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Figure 2-1: Long Bone1 
 
There are two types of bone based on the amount of structural material present.  Compact bone 
is dense, low-porosity (5-10%) bone tissue that forms the outer shell of bones [25].  Because it is 
located at the cortex, it also goes by the name cortical bone.  Cortical bone comprises 
approximately 80% of total bone mass, and is thickest in the shaft of long bones.  Its role is 
primarily structural.   
Cancellous (also spongy or trabecular) bone forms the interior volume of bone encompassed by 
the cortical shell.  (Although, the shafts of long bones are notably absent of cancellous bone.  
The space—known as the medullary cavity—is reserved for fatty yellow marrow.)  The porosity 
of trabecular bone is typically 75-95% [25].  The space is commonly filled with red marrow, 
which is responsible for the creation of blood cells.  Unlike cortical bone, whose structure 
appears more or less uniform without magnification, cancellous bone looks like an open-cell 
foam.  The rods connecting the nodes of spongy bone are termed trabeculae (sing. trabecula).  
They can exhibit a wide range of shapes, but are most often 0.1 to 0.2 mm in diameter and on 
the order of 1 mm long.  The exact architecture of the bone can vary widely on a continuum 
from rod-like to plate-like.      
                                                            
1 Public Domain: http://training.seer.cancer.gov/anatomy/skeletal/classification.html 
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2.1.1.2 Microanatomy 
At the microscopic level cortical bone is composed of osteons running down the longitudinal 
axis of the bone.  Each osteon is a cylindrical unit composed of concentric layers (lamellae) of 
bone tissue.  At the center of the osteon is a hollow core, the Haversian canal, which provides a 
passageway for blood vessels and nerves.  The Haversian canals are connected transversely by 
Volkmann’s canals, creating a network throughout the bone.  Osteons have an outer diameter 
of roughly 0.2-0.3 mm, and an inner diameter of about 0.05 mm. The lamellae range in thickness 
from 3 to 10 microns.  All of the structures are shown (not to scale) in Figure 2-2. 
Trapped between the lamellae are osteocytes, mature bone cells.  The space they reside in is 
called a lacuna, and is about 8 microns in the long axis, but varies from 3-20 microns [26].  The 
lacunae are connected via a network of narrow passageways termed canaliculi.  They are about 
225 nm in width, and vary in size depending on whether they are circumferential (between 
lamellae) or radial (crossing lamellae) [27].   
Cancellous bone, like cortical bone, is composed of lamellae.  Unlike in cortical bone, the 
lamellae are not arranged into osteons.   They form irregular patterns just a few layers thick.  
Aside from their arrangement, the lamellae themselves are the same in trabeculae and osteons.  
The load-bearing extracellular material of bone is essentially the same regardless of where it is 
found.  The material is a composite of organic proteins and inorganic mineral (hydroxyapatite: 
Ca10(PO4)6(OH)2)).  The proteins are 90% collagen, with type I collagen fibers being the dominant 
variety.  The fibers are oriented in the same direction within a given lamella, but lamella 
orientations differ, not unlike the layers in a sheet of plywood.  Collagen has a low elastic 
modulus (around 6 GPa), but is has a large strain at failure, making it tough.  Bone mineral is stiff 
and brittle, and it accounts for three fourths of dry-bone weight.  Single crystals of 
hydroxyapatite have a modulus of 54-79 GPa [28].  (For comparison, the Young’s modulus of 
aluminum is 70 GPa.) The modulus of bone tissue fluctuates based on patient, anatomical site, 
and orientation, but generally falls around 10-20 GPa.  The failure stress varies from ~50MPa in 
tension perpendicular to the collagen fibers, to ~190 MPa for compression parallel to the fibers.    
It is important to bear in mind that when mechanical properties are reported for cancellous 
bone they are often given at the apparent level, which treats the entire structure of the bone 
like its own homogeneous material.  The resulting values for young’s modulus and strength are 
drastically reduced from the material level due to the reduced volume fraction.   That being said, 
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there is some evidence that cancellous bone is more compliant than cortical bone, even at the 
material level [29].  
Figure 2-2: Cross Section of Diaphyseal Bone2 
 2.1.2 Physiology 
Bone is often thought of as static by the uninitiated.  To the contrary, it is a dynamic organ that 
is constantly regenerating itself.  The rate of bone remodeling (or turnover) is dependent on 
anatomical location and bone type.  In normal adults, 4-5% of cortical bone is renewed each 
year.  The space between osteons is filled with interstitial lamellae, which are fragments of 
previously whole osteons that were partially destroyed by remodeling. Trabecular bone is 
remodeled to the tune of 20-25% per year.  Bone remodeling repairs microcracks that appear in 
bone as the result of normal activity.  It also adjusts the amount of bone by location depending 
on the applied loading, which is why astronauts lose bone mass in space and why athletes have 
increased bone density tailored to their sport’s demands.  (The concept of bone adapting to 
stress is known as Wolff’s law.) Lastly, remodeling is used to heal fractures.  Initially, the 
collagen matrix of freshly-repaired bone is an unorganized web.  The so-called woven bone is 
generated quickly, but it is weaker.  Remodeling gradually replaces the woven bone with 
lamellar bone.   
                                                            
2 Public Domain: http://training.seer.cancer.gov/anatomy/skeletal/tissue.html 
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The process of bone remodeling starts with activation, which may be brought on by a fatigue 
crack severing bone lining cells (and osteocytes).  After detecting the biochemical signal of the 
distress, stromal cells differentiate into osteoclasts.  Osteoclasts are large multi-nucleated cells 
which resorb bone mineral for 2-3 weeks before undergoing apoptosis.  Their ruffled edge and 
specialized proteins allow them to seal against the surface of exposed mineralized bone.  Once 
connected, they use carbonic acid to dissolve the extracellular matrix (ECM).  The next stage, 
reversal, takes about 2 weeks, during which time the osteoclasts undergo apoptosis.  Formation 
begins with the creation of osteoblasts from stromal cells.  The osteoblasts fill the resorption pit 
with osteoid, which is new unmineralized bone.  Osteoid is a network of predominantly parallel 
cross-linked collagen fibers which lay the framework on which mineral will later be deposited.   
As the osteoblasts work, some of them trap themselves within the osteoid.  When the bone 
matures, those cells become the osteocytes described earlier.  Osteoblasts left at the surface of 
the bone become bone lining cells.  The formation phase is the most time-consuming part of 
bone remodeling, taking anywhere from 3 to 6 months.  However, the bone will continue to 
gather mineral and increase in hardness for years.  Collectively, bone remodeling cells form a 
BMU, or basic multicellular unit.  The time required to complete a remodel at a particular site is 
the bone remodeling period.     2.1.3 Pathology 
 Due to the complex signaling pathways responsible for regulating bone turnover, bone is 
susceptible to several pathologies.  By far, the most common is osteoporosis.  The standard 
definition of osteoporosis in women, as set by the World Health Organization, is having a bone 
mineral density (BMD) t-score of -2.5 or less.  The t-score is the number of standard deviations 
the patient BMD lies from the mean BMD of a 20-year-old reference population.  Z-scores are 
also used in diagnosis; they reference an age-matched population.    
Osteoporosis may be sorted into two categories: primary and secondary.  Primary osteoporosis 
occurs naturally due to the inevitable decline of bone mass after age 30.  It is a natural, if 
unpleasant, part of the human condition.  Primary osteoporosis is itself separated into two more 
groups: Type I and Type II.  Type I, or high-turnover, osteoporosis presents itself before the age 
of 70 and is most common in post-menopausal women.  Type II, or senile, osteoporosis is 
observed in patients over 70 and is caused by a gradual thinning of cancellous and cortical bone.   
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Finally, secondary osteoporosis has a clearly discernible cause, such as the use of corticosteroids 
or anticonvulsants.   
This research focuses primarily on type I osteoporosis, since it is the most prevalent variety.  The 
precipitous decline in estrogen levels after menopause adversely affects bone turnover.   
Estrogen is at least partially responsible for osteoclast apoptosis, and for suppressing the 
production of osteoclastogenic cytokine [30].  With more osteocytes being formed, and fewer 
osteocytes dying on command, the balance of bone resorption to formation is set up for the net 
destruction of bone.  Treatments generally serve to either increase osteoblast activity, or 
decrease osteoclast activity.  Bisphosphonates take the latter approach.  2.1.4 Bisphosphonate Function 
Bisphosphonates are similar to naturally-occurring pyrophosphate, but with the central oxygen 
atom replaced by a carbon atom and two side chains.  Because bisphosphonates have an affinity 
for calcium, they selectively target the ECM of bone.  When osteoclasts begin the remodeling 
process, they ingest the bisphosphonates, which leads to early apoptosis by interfering with the 
normal uses of pyrophosphate.   The decreased osteoclast activity slows the rate of bone loss, 
thereby reducing the risk of fractures.   
Depending on the chemical composition of the two side chains, bisphosphonates have potencies 
that vary by orders of magnitude.  Non-nitrogen-containing varieties were the first to be 
developed.  Etidronate, the first bisphosphonate used to treat osteoporosis, had a methyl group 
and a hydroxyl group.  It interrupts the Krebs cycle of osteoclasts by forming a non-functional 
version of ATP.  Using etidronate as a unit of potency, other non-N containing drugs were 
developed with potencies of 10.  Second generation bisphosphonates contain nitrogen in their 
side chains, and have potencies ranging from 100 (pamidronate) to 1000 (ibandronate). Their 
mechanism of action is to inhibit farnesyl pyrophosphate synthase in the HMG-CoA reductase 
pathway.  Third generation bisphosphonates have a heterocyclic nitrogen-containing ring in one 
of their side chains.  Risefronate has a potency of 2000, and zoledronate a potency of 10,000. 
The type of bisphosphonate was not a controlled variable in this research, but the majority of 
non-control patients were on second generation bisphosphonates at the time of biopsy. 
Oral bioavailability of bisphosphonates is poor (<5%), but of the dose that makes it to the 
bloodstream, approximately half is absorbed by the bone with the remainder being expelled in 
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urine [31].  Once in bone, bisphosphonates can remain there for up to 10 years [31].  Because 
oral intake can upset the stomach and esophagus, ibandronate is available as a quarterly 
injection, and zoledronate as a yearly injection.  The long intervals between treatments are 
possible because of bisphosphonate’s permanence in the ECM of bone tissue.   
There is widespread agreement that bisphosphonates are beneficial to bone strength in the 
short term.  However, there is dissonance in the community about their efficacy and safety in 
the long term (>5 years).  Suspicions were raised when an increased occurrence of atraumatic 
fractures were observed in bisphosphonate patients.  An atraumatic fracture is defined as any 
fracture occurring during normal activities.  Any event more serve than a fall from standing 
height is considered traumatic.  For the most part atraumatic fractures are synonymous with 
low-energy fractures, pathologic fractures, spontaneous fractures, fragility fractures, fatigue 
fractures, and insufficiency fractures.   
The observation of low-energy fractures in long-term patients does not prove that 
bisphosphonates are the cause, but the correlations are striking nonetheless.  A retrospective 
review by Neviaser et al. in 2008 identified 70 low-energy fracture patients admitted to the 
Hospital for Special Surgery [32].  Twenty-five of the patients were using alendronate, of which 
19 presented with “a simple, transverse fracture with a unicortical beak in an area of cortical 
hypertrophy”.  Only one of the 45 non-bisphosphonate patients showed a similar fracture 
pattern.  The 19 patients with the fracture pattern had been taking alendronate for an average 
of 6.9 years, compared to only 2.5 years for the 6 patients without the pattern (p=0.002).   
Atypical femoral fractures have been observed in bisphosphonate patients by other researchers 
as well, notably Meulen and Boskey [33].   
It has been hypothesized that the rash of atraumatic fractures may be the result of unrepaired 
microdamage.  With less osteoclast activity, the cracks that naturally form as a part of daily 
activities cannot be repaired at the necessary rate. As time passes while on bisphosphonate 
treatment, it is suspected that the cracks proliferate in number, increase in length, and coalesce.  
Eventually, the accumulation of microdamage results in global failure.  In concert with the 
microdamage, changes are observed in the microarchitecture of the cancellous bone.  Both 
factors play a role in determining overall bone strength.   
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2.2 Basics of Finite Element Analysis 
The finite element method (FEM) is an approach for solving partial differential equations over 
geometrically complex domains.  The method works by solving the equations over a simple 
domain, a rectangle for example.  By combining many rectangles, it is possible to create complex 
shapes.  Using small enough rectangles, any object can be well-represented, just as pixels can 
characterize an image.  The simplified domain is called an element, and a finite number of them 
are used to form the global geometry.  Depending on the problem at hand, elements may be 
lines, triangles, quadrilaterals, tetrahedrons, hexahedrons, or any shape which allows the PDE to 
be solved.   
The phrase “finite element method” was first coined by Ray W. Clough in 1960, but the work of 
Argyris, Courant, Turner, and Zienkiewicz all contributed to the method’s development [34].  
Today, FEM has been applied to PDEs for heat transfer, fluid flow, and electromagnetic fields, 
but it was originally developed for the analysis of aircraft structures.  The method has enjoyed 
widespread use to determine stress and strain in complex structures [35], and when applied 
correctly it closely matches experimental data [36]. The behavior of most structural engineering 
materials is approximated by the equations of linear elasticity.  
The governing equations of linear elasticity are the equations of motion, the strain-displacement 
relations, and the constitutive equations.  Using indicial notation, the equations of motion 
reduce to the following for static problems: 
𝜎𝑗𝑖,𝑗 + 𝐹𝑖 = 0 
The strain-displacement relation is given by: 
𝜀𝑖,𝑗 = 𝑢𝑖,𝑗 + 𝑢𝑗,𝑖2  
The constitutive relations describe the interaction of stress and strain.  For an isotropic material: 
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To calculate the element equations, the variational (weak) formulation of the governing 
differential equation is first developed.  The weak form is the result of multiplying both sides of 
the equation by an arbitrary weight function and integrating by parts to “move” differentiation 
from the unknown function to the weight function. The solution is then assumed to have a pre-
determined form.  For instance, in a two dimensional problem the solution between the nodes 
may be assumed to be a straight line.  Based on that pretense, the solution to the governing 
equation is determined solely by the values at the nodes.  However, that simplified piece-wise 
solution will not satisfy the governing equation at every point, which is where the weight 
function comes into play.  Using the Ritz method, the solution is made to satisfy the weak 
formulation at the nodes by manipulation of the weight function.  The equations that result 
from imposing the nodal values are the algebraic element equations.   (Alternatively, the 
element equations can be derived based on energy principles for structural problems.)   
With the element equations in hand, the relationship between force and displacement can be 
written for every element in the domain.  The local equations contain too many unknowns to be 
solved, so the equations are combined and rewritten in terms of global nodes.  Boundary 
conditions (known nodal displacements) are then applied to the model and the equations are 
solved.   2.3 Prior Work  2.3.1 Bisphosphonate Studies 
There have been a plethora of studies performed to measure the effectiveness and safety of 
bisphosphonate treatment.  A 2009 review of bisphosphonates by Bilezikian stated that “trial 
extensions of up to 10 years with alendronate and 7 years with risedronate have shown that 
efficacy is maintained during long-term treatment” [37].  In a separate study, Pazianas et al. 
concluded that all approved bisphosphonates reduce the risk of both vertebral and non-
vertebral fractures [38].   
On the other hand, there is evidence to suggest that bisphosphonates may lose efficacy, or 
potentially even be unsafe with long-term use. Allen and Burr have done extensive research on 
the effect of alendronate treatment in canines.  One of their more benign findings was that 
alendronate treatment did not continue to decrease trabecular stresses after 1 year of 
treatment [39].  More disconcerting is that, when adjusting for aBMD, 1 year of alendronate 
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treatment reduced bone’s energy to failure in beagles [40].   However, it is unknown exactly 
how a decrease in tissue-level properties affects whole-bone strength [41].     
Research on human subjects has also revealed some cause for concern regarding long-term use.  
In a press release on October 13th, 2010, the FDA announced that there may be an increased risk 
of atypical femur fractures after bisphosphonate use for more than 5 years [42]. Because 
bisphosphonates remain in the bone after treatment, they continue to provide some level of 
effect after patients discontinue use.  Based that fact, and on suspicions of long-term detriment, 
several studies have suggested taking a “drug holiday” [43,44].  The start time and duration of 
the suggested holiday depend on patient specifics, but 5 years was a common recommendation 
for patients at a mild fracture risk.  The presence of this somewhat arbitrary 5-year value in the 
literature is what dictated the division between short and long-term groups in the present 
research.       
The role of microdamage in bone strength, and specifically in bisphosphonate patients, has been 
extensively studied.  Yet, there is still no way to quantify the effect microcracks have on whole 
bone strength.  Research has been done which quantifies the amount of microdamage and then 
determines bone strength by experiment, but there is no established technique to predict 
strength from microdamage information.  It is difficult to isolate the contribution of 
microdamage to whole bone strength due to confounding variables like degree of mineralization 
and microarchitecture [45].  There is evidence that bisphosphonates do indeed lead to 
unrepaired microdamage accumulation in dogs [45,46].  As is to be expected there is evidence 
to the contrary as well.   Chapurlat et al. have observed from transiliac biopsies in humans that 
long-term bisphosphonate use does not lead to increased microdamage [47].  Because of the 
difficulty of assessing the influence of microdamage on bone strength, and the impractical 
nature of measuring the three dimensional geometry of a crack, microdamage was not 
incorporated into the finite element model of this thesis.  2.3.2 The FEM in Medical Studies 
As previously mentioned, the finite element method is not a new tool, and the medical field was 
not slow to adopt it.  It has been used to study knee replacement, ear acoustics, car crash 
injuries, the mechanics of the heart, and cell dynamics.  Concerning cancellous bone, current 
FEA-based research can be categorized by the resolution of the method used to generate the 
geometry.   
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In order to have a truly representative model of bone, the resolution must be small enough to 
capture the microarchitecture.  The importance of architecture in the strength of cancellous 
bone is difficult to overstate.  Improved microarchitecture leads to increased bone strength in 
rats [48], poor architecture has been seen in women with idiopathic osteoporosis [49], and low 
bone strength in turner syndrome patients has been linked to poor microarchitecture [50].  
Without a small enough resolution, the input of trabecular connectivity, width, spacing, and 
orientation are all lost.  
Those technologies with the ability to scan the largest areas, such as quantitative computed 
tomography (QCT) also have the lowest resolutions.  As a result, they cannot model the 
microarchitecture of the cancellous bone.  Instead, they treat cancellous bone like a solid and 
weigh the material properties of each voxel-element based on the average radiodensity at that 
location.  Using QCT with a cubic voxel size of 1.5mm, Amin et al. found that “FE-derived 
estimates of proximal femur strength are comparable in determining the probability of 
prevalent overall and osteoporotic fractures to total hip aBMD or vBMD” [51]. At 7T field 
strength, µMRI can achieve a resolution of 137 x 137 x 410 µm3, which is sufficient to capture 
some microarchitecture [52].  Though, it leaves a lot to be desired seeing as how trabeculae are 
often thicker than 137 µm.   
All of the methods used to achieve finer resolutions sacrifice field of view to do so.  The next 
step down in the continuum is high-resolution peripheral computed tomography (HR-pQCT). 
Like QCT and MRI, HR-pQCT can be used to measure in-vivo bone geometry, but it is limited to 
the extremities.  It is capable of resolutions in the neighborhood of 80 µm.  Despite some 
trabeculae being less than 80 µm in diameter, HR-pQCT has produced many promising results.  
Boutroy et al. performed a finite element analysis on the distal radius of postmenopausal 
women and found that FEA may offer information about fracture risk not provided by BMD or 
architectural parameters [53].  Pistoia et al concluded that microFE is a better predictor of bone 
failure than DXA measurements and structural parameters combined [54].  Since HR-pQCT has 
been established as a respectable method for mechanical analysis of bone, it has been used to 
study osteoporosis, bisphosphonates, and other osteoporosis treatments.  However, few, if any, 
have focused on the long-term effects of bisphosphonates.  
To obtain better resolution than HR-pQCT can offer, it is necessary to switch to a microCT 
specimen scanner.  The resolution acquired by a specimen scanner depends on the size of the 
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object being scanned.  In the case of the SCANCO microCT 40, the best resolution is around 8 
µm (10% MTF) at a sample diameter less than 12.3mm.  The SkyScan2011 has a resolution of 0.4 
µm (10% MTF), but the sample diameter must be less than 1mm.  Of course, since all specimen 
scanners require human tissue to be ex-vivo, the relevance of FEA is slightly diminished.  The 
bone could simply be physically tested to obtain true force-displacement curves.  FEA is still of 
some benefit because physical testing can only be completed to failure once, whereas FEA can 
run as many simulated loading cases as desired.  Obtaining a large, i.e. representative, sample of 
bone for analysis typically requires using animals or cadavers, both of which have their 
disadvantages.  Dead bone cannot be labeled with tetracycline to determine bone turnover 
parameters, and any animal study cannot be directly applied to humans.  To fix both of those 
problems, at the cost of total bone volume, human bone biopsies can be studied.  However, 
relatively few finite element studies use biopsies as their main object of study, and even fewer 
are focused on bisphosphonate duration.  This is unfortunate, because Harrison et al. have 
observed excellent correlations between microCT-derived FEA and experimental results when 
studying ovine trabecular bone [55].   
To summarize, the finite element method is a firmly established weapon in the medical research 
arsenal.  The type of finite element model developed depends on the resolution of the scan, and 
all else equal, higher fidelity results are obtained at higher resolutions.  The finite element 
method has been applied to the study of bone before, but little work has been done regarding 
the FE analysis of ex-vivo bone biopsies from long-term bisphosphonate patients.   
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3 Methodology 3.1 Selection Criteria 
Of the roughly 700 osteoporotic biopsies eligible for participation in the study, hundreds had to 
be rejected based on the controlled variables (and/or lack of necessary metadata).  Restricting 
the study to post-menopausal patients reduced the candidate pool by 223. Applying the 
constraint of non-diabetic patients further lowered the number of eligible biopsies by 194.  An 
additional 20 patients were rejected due to a history of smoking, and eight were removed due 
to use of Forteo.   After applying all of the filters, only 87 patients with low-turnover 
osteoporosis were available.  Of those 87 patients, 16 had no history of bisphosphonate use, 29 
had between one and five years of bisphosphonate use, and 22 had more than five years of 
bisphosphonate use.  (The balance lacked information or had less than 1 year of use.) Lastly, the 
three experimental groups were selected such that there was no statistically significant 
difference in patient age.   
The controlled variables were maintained, at the sacrifice of sample size, because they all have 
an effect on bone strength [56], and potentially on the efficacy of bisphosphonates.  By reducing 
as many of the confounding factors as possible, it was hoped that the small sample size could 
yield useful results.  Inconveniently, the sample sizes were further reduced by the fact that not 
all of the biopsies were suitable for structural analysis.  The ideal biopsy was a right circular 
cylinder, comprised primarily of cancellous bone, similar to that shown Figure 3-1.  Deviations 
from the ideal included presence of excessive cortical bone (Figure 3-2), tapered geometry, 
curved geometry, and fragmented pieces.    
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Figure 3-1: Candidate for Analysis 
 
Figure 3-2: Poor Quality Biopsy 
 
 Having removed all of the ineligible biopsies, and matching as closely as possible for age, the 
final result was three groups of 10 biopsies.  A summary is presented in Table 3-1, and the 
complete set of biopsy metadata can be found in Appendix F.  
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Table 3-1: Experimental Groups 
 
Age (Years) Duration (Years) 
Group Mean SD Mean SD 
Control 57.1 11.03 0 0 
Short Term 58.2 2.62 2.38 1.08 
Long Term 60.6 4.60 7.75 2.82 
 
To summarize, the controlled variables were: gender, menopause, history of smoking, Forteo 
use, turnover (low), and age.  As a result of these restrictions, ethnicity (Caucasian) happened to 
be constant across the experimental groups.  The uncontrolled variables of interest were: 
exercise frequency, bisphosphonate dosage, calcium intake, ethanol abuse, fracture history, use 
of hormone replacement therapy, use of proton-pump inhibitors, presence of mineralization 
defect, and oophorectomy status.    3.2 Biopsy Preparation 
The biopsies were not collected specifically for this study.  As previously stated, they were a pre-
existing resource.  Nonetheless, it is necessary to know how they were collected in order to 
grasp the context of the results.  All biopsies were taken from the ilium (Figure 3-3).  Most were 
vertical biopsies extracted from the iliac crest, but a minority was transiliac.     
Figure 3-3: Pelvic Girdle3 
 
                                                            
3 Public Domain: http://training.seer.cancer.gov/anatomy/skeletal/divisions/appendicular.html 
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After being extracted, the “bone samples were fixed with ethanol at room temperature, 
dehydrated, and embedded in methylmethacrylate” (Malluche et al., 2012).  
Polymethylmethacrylate (PMMA) is more commonly known as acrylic, but also goes by the trade 
names Plexiglas, Perspex, and Lucite.   
Note that some of the biopsies were cut roughly in half in order to perform histological analysis 
(Figure 1-3). The reduction in usable volume is a hindrance to the finite element analysis, but it 
was unavoidable.   In the future, microCT scans should be performed prior to preparing the 
biopsy for histology.   3.3 MicroCT Scan 3.3.1 Overview 
Once the biopsies were embedded in acrylic, they were processed using a SCANCO microCT 40.  
The machine itself is a desktop device, weighing approximately 150 kg.  For a sense of scale, 
refer to Figure 3-4. 
Figure 3-4: MicroCT Instrumentation 
 
The three-dimensional representation of the biopsy is created by first passing a small-angle 
cone-beam of x-rays through the sample.  As the x-rays travel through the biopsy, the bone 
mineral absorbs the radiation at a higher rate than the acrylic around it.  After finishing their 
journey through the specimen, any remaining x-rays arrive at a scintillator, which converts the x-
rays into visible light.  The visible light is then converted into an electronic image using the now-
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commonplace charge coupled device.  From any one perspective, the resulting projection would 
not be particularly useful.  So, the biopsy is rotated 360 degrees as many images are taken.  For 
each slice location, this collection of images is compiled into a sinogram, which is a physical 
analog for the Radon transform of the slice.  (Mathematically, an infinite number of projections 
are required, but a reasonable degree of accuracy is obtained from a finite number of scans.) 
Figure 3-5 depicts a sinogram from one of the biopsies in the study. 
Figure 3-5: Sinogram of B02 (Slice 50) 
 
In order to reconstruct the geometry of the cross-section, the inverse Radon transform is 
performed on the sinogram.  Each pixel in the resulting cross-sectional image is a measure of the 
radiodensity of that portion of the sample.   The entire image generating process is repeated for 
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each desired layer, resulting in a large collection of 2-D information. Since the layers are spaced 
close together in relation to the resolution of the images, it is feasible to render the 3-D bone 
volume.  The process of converting the slices into a volume can be accomplished by a variety of 
techniques, the details of which are beyond the scope of this thesis.   3.3.2 Detailed Procedure 
In order to perform the scan, first an appropriate sample holder had to be selected for the 
potted biopsy.  SCANCO provides sample holders in both PMMA and PEI materials, with the 
latter offering better chemical resistance and a wider temperature range than the former.  Since 
the biopsies in this study were a room temperature solid, either material was permissible.  The 
holders also come in an array of diameters, from 12.3mm to 36.9mm.  The acrylic block had an 
outer diameter of roughly 16mm, so the 20.5mm sample holder was selected.  In Figure 3-6, the 
sample holder, complete with biopsy, has been loaded into the microCT.    
Figure 3-6: Sample Loaded into µCT Scanner 
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It is important to fully constrain any motion between the sample and the sample holder.  The 
sample holder spins as x-ray projections are gathered, and during the computed tomography it 
is assumed that the specimen rotates with the holder.  In order to fix the biopsy to the holder, a 
piece of foam was inserted into the sample holder.   The foam was oversized for the diameter of 
the tube, and the friction from the resulting interference fit was sufficient to apply a 
compressive force onto the top of the biopsy. 
Once loaded into the microCT, a quick scout view was performed to define the portion of the 
sample holder which should be scanned.  The thinner the scout view region, the faster the 
subsequent full-resolution scan will be completed.  Figure 3-7 shows a representative scout view 
with the biopsy, acrylic, and sample holder visible. 
Figure 3-7: Scout View of Biopsy B22 
 
 
Before starting the scan, a control file must be defined and selected.  Figure 3-8 shows the input 
window for control file creation.  The first section dictates the scout view settings, which are 
predominantly a matter of convenience.   The settings do not affect the final scan geometry.  
The central section contains the most critical settings, chiefly the field of view (FOV) and the 
resolution.  The FOV must not be less than the diameter of the sample holder, or else the 
instrumentation will collide with the object under study.   For this study, the FOV was set at 30.7 
mm, and the resolution at 1024x1024 pixels.  The resulting voxel size is 30 microns.  A higher 
resolution could have been obtained, but was not used on the recommendation of fellow 
microCT users.  Naturally, the higher resolution scans take more time, and so do all of the 
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secondary operations.  They also require vastly larger amounts of memory.  The final section of 
the input control file is reserved for calibration and evaluation.  Calibrations were performed as 
regularly scheduled, independent of this research, and the evaluation was selected at a later 
stage.   
Figure 3-8: Control File Settings 
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For the settings described, a typical biopsy (3mm, 100 slices) required approximately 15 
minutes to scan. Having completed the scan, the individual slices are displayed from SCANCO’s 
evaluation window. 
Figure 3-9: Evaluation Window 
 
From this window, two major objectives are accomplished.  First, the region of interest (ROI) is 
defined.  Secondly, the threshold between bone and acrylic is established.  To demarcate the 
region of interest, lines were hand-drawn around the biopsy.  Thankfully, this is only necessary 
on a subset of slides.  Provided the cross section does not change too drastically, the SCANCO 
software can morph the ROI from non-consecutive slices onto the set of bounded slices.  For STL 
file creation there was no effort made to contour the biopsies.  As long as the ROI contained the 
entire biopsy the STL would also contain all of the geometric information.  However, for 
calculation of structural indices, an overly large ROI would not be acceptable.  For instance, it 
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would greatly reduce BV/TV.  To calculate structural indices, the ROI encompassed only the 
trabecular bone.  Figure 3-10 shows the cancellous ROI defined on a specific slice.   
Figure 3-10: Region of Interest, Slice 48 
 
 
With the ROI set, a threshold must be dictated between what is, and what is not, bone tissue.  
For this study, a constant value of 184 mg HA/cm3 was selected as the threshold.  The value was 
based the recommendation of University of Kentucky graduate students experienced with 
scanning bone tissue.  It is worth future study to determine what threshold criteria yields the 
highest fidelity geometry.  For example, tailoring the threshold value based on the absorptivity 
histogram may lead to improved results.  That being said, the method utilized in this study 
produced satisfactory results as evidenced by Figure 3-11. The radiodensity composition of the 
entire cross section is shown in Figure 3-12, with the structural bone tissue in white and all other 
material in black.  
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Figure 3-11: Greyscale (Left) and Thresholded (Right) Slices 
 
Figure 3-12: Histogram of X-ray Density in Slice 48 
 
 
Following the designation of the ROI and threshold value, an entire suite of analyses may be 
executed.  Histomorphometric analyses can be performed in 2D and 3D, DICOM files can be 
created, and the geometry can be exported as an STL file.  Most of the analyses are 
computationally intensive; consequently, the proprietary SCANCO software does not run on a 
typical desktop computer.  Rather, it utilizes an HP integrity server running the OpenVMS 
operating system.  To create the STL file, the “3D segmentation of VOI” procedure was run from 
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the evaluation window.  The segmentation evaluation generates a file with a seg_aim extension, 
used as the input for the STL generation.  The STL file is created using SCANCO’s Image Process 
Language (IPL).   Figure 3-13 shows a sample of the command window used to interface with IPL.  
Figure 3-13: SCANCO IPL User Interface 
 
 
The STL file format has its roots in rapid prototyping, specifically additive manufacturing via 
stereolithography.  The file itself encodes the geometric information by defining a large number 
of triangles.  Each triangle is assigned an outward normal vector, and the points forming the 
triangle are defined by three Cartesian coordinates.  In light of that, it is easy to see why STL is 
an acronym for Standard Tessellation Language [57]. The individual triangles do not have to 
possess any structure—such as connectivity or watertightness—they are completely raw. While 
that makes STL files very flexible, it is not helpful when conducting a finite element analysis.  The 
surface geometry can suffer from holes, duplicate vertices, duplicate faces, zero area faces, and 
a litany of other problems. These issues must be resolved prior to any attempt to create a mesh. 3.4 Mesh Geometry Refinement 
MeshLab is an open source program widely used to process unstructured triangular meshes, 
which was produced with the support of the 3D-CoForm project.  It accepts the majority of 
common file formats, including STL. The software was created specifically with large files from 3-
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D scanning in mind [58].  Due to that focus, MeshLab includes numerous automatic cleaning and 
repairing tools.   
Importing the biopsy STL file into MeshLab v1.3.1 is as simple as selecting ‘File>Import Mesh’ 
from the menu bar.  MeshLab automatically unifies duplicate vertices and scales the geometry 
to fit within the viewing area.  Typically, there are many free-floating pieces in the freshly-
imported STL mesh.  The finite element analysis requires one single body (with appropriate 
boundary conditions) in order to avoid rigid body motion.  To eliminate the extraneous pieces, 
the command ‘Filters>cleaning and repairing>remove isolated pieces (wrt diameter)’ was issued.  
For all of the biopsies in this study, a diameter of 4 mm was used.  The biopsy length always 
exceeded that value, and any unwanted portions of the geometry larger than 4 mm were easily 
removed by manual selection.  Figure 3-14 shows biopsy B01 prior to applying the filter, with a 
few of the free-floating pieces circled in red.  Notice that one piece is quite small; removing all 
the fragments this size manually would be prohibitively difficult. After applying the filter, as 
shown in Figure 3-15, the unwanted volumes are no longer present.   
Figure 3-14: STL Geometry Prior to Size Filter 
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Figure 3-15: STL Geometry after Size Filter 
 
After removing separate bodies, the biopsies must be aligned for the simulated compression 
test in ANSYS.  This alignment could have been performed by placing the biopsies in the SCANCO 
sample holder at a consistent angle.  However, that would only partially solve the problem.  
Some biopsies were embedded into the acrylic at an angle to the bottom surface; i.e. they did 
not lie flat on the bottom of the block.  Without a digital realignment, either the block would 
have to be machined, or the biopsy would have to be re-embedded.   As for digital alignment, 
there were multiple avenues considered.  The first attempt involved creating a new coordinate 
system in ANSYS, which would have had to have been done for each biopsy individually.  So as 
to generate consistent ANSYS input, the alignment was done within MeshLab.  Rather than 
manually altering the angle and using human judgment to decide when the biopsy was 
satisfactorily aligned, each biopsy was aligned with its principal axis.  The command to do so is 
‘Filters>Normals, Curvatures and Orientation>Transform: Align to Principal Axis’.     
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Figure 3-16: B019-09 Biopsy Alignment 
 
Occasionally the transformation would align the biopsy with the horizontal, rather than the 
vertical axis.  In those cases, a 90 degree transformation was applied with ‘Filters>Normals, 
Curvatures and Orientation>Transform: Rotate’. The method of aligning to the principal axis 
worked best on biopsies with large aspect ratios.  At small aspect ratios, the principal axis is 
dictated by the microarchitecture of the cancellous bone, and not by the axis of the core drill 
used to harvest the biopsy.   Furthermore, a large amount of unevenly distributed cortical bone 
can visibly skew the alignment.  In those cases, the cortical bone was removed using Netfabb 
Studio Basic, and then realigned with MeshLab.   
 Netfabb is another common tool for editing STL files, but unlike MeshLab it is not open source.  
The full version of the software, Netfabb Studio Professional is only freely available as a 30-day 
trial.  However, the basic version of the software is freely distributed without a time restriction.  
BEFORE AFTER 
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Serendipitously, both versions allow an STL file to be cut.  Figure 3-17 shows a biopsy with its 
cortical bone still intact, and Figure 3-18 displays the biopsy after being cut with Netfabb v4.9.2.   
Figure 3-17: Biopsy B07 Prior to Netfabb Cut 
 
Figure 3-18: Biopsy B07 after Netfabb Cut 
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Biopsy B07 has two distinct regions of cortical bone, but even so, it was difficult to define exactly 
where cortical bone ended and cancellous bone began. Throughout this project, there was no 
consistent method to determine the border between the two types of bone; it had to be 
reevaluated on each biopsy. Some biopsies did not display any clear distinction between cortical 
and cancellous bone.  Those biopsies were still cut at both ends for the following reasons: 1) A 
flat surface is convenient for the application of boundary conditions in the FE analysis, 2) The 
ends frequently tapered off or kinked, and 3) It allowed for a more consistent treatment of all 
the biopsies.  After making the cuts, a piece of previously-connected bone would occasionally 
become separated from the main body.  In this event, the STL was transferred back to MeshLab 
for clean-up.  (Note that MeshLab processing must precede the cutting because Netfabb only 
cuts along the three orthogonal coordinate planes.)  
Netfabb was also useful in repairing holes in the STL geometry. The problem with holes only 
manifests itself when attempting to create a solid mesh from the STL shell, so only those 
biopsies which could not initially be meshed were repaired in Netfabb.  No modification from 
the default repair was necessary.  Upon saving the repaired file, it was sometimes necessary to 
split manifold edges.  A repair tolerance of 2 microns was accepted because, at 1/15th the scan 
resolution, it was unlikely to appreciably alter the geometry.   
Figure 3-19: Netfabb Default Repair 
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Figure 3-20: Two Micron Repair Tolerance 
 3.5 Mesh Generation 
The STL mesh is just a shell representing the exterior surface of the bone.  In order to perform a 
structural analysis, the mesh must represent the entire bone volume.  Many commercial 
software packages are available which can mesh volumes enclosed by STL files, such as 
Rhinoceros, Mimics, ANSYS ICEM, Tgrid, and Hypermesh.   ANSYS ICEM v14.0 was the tool of 
choice during this research for its intuitive user interface and widespread availability on site at 
the University of Kentucky. 
After having filtered, aligned, and cropped the STL file, it was imported into ICEM with the 
command ‘File>Import Geometry>STL’.   Typically, the geometry was not displayed on screen 
because of the large number of facets.  (If desired, the imported surface can be forced to appear 
from the menu tree.)  Next, the meshing parameters were defined.  The final parameters chosen 
were the result of extensive thought and study, the specifics of which can be found in the Mesh 
Convergence Study section of this document.   
The parameters defined for the volume mesh are divided into three menus: the global mesh 
parameters, the volume mesh parameters, and the mesh computation parameters.  The global 
mesh parameters used in this study are shown in Figure 3-21.   
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Figure 3-21: Global Mesh Settings 
 
The global scale factor was left at the default setting of 1 because the STL output from the 
microCT is automatically provided in the actual-size of the specimen.  The maximum element 
size was set to 250 microns.  Most elements in the final mesh were below the maximum 
element size because proximity based refinement was enabled.  The benefit of using this 
method is that it reduces the total number of elements in the model.  If the max element size 
were selected to give a good representation of the geometry, it would result a mesh with too 
many elements.  By using larger elements where there were thick regions of material, and 
smaller elements in the thin trabeculae, the total element count was reduced while conserving 
model fidelity.  In addition to the global settings, there were also specific settings for the volume 
mesh (Figure 3-22).   
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Figure 3-22: Volume Mesh Settings 
 
The mesh type can be tetra/mixed, hexa-dominant, or Cartesian.  Within the category of tetra 
meshing, the methods available in ICEM are Octree, Delaunay, and advancing front. The hexa-
dominant method produces a layer of hexa elements at the surface of the volume, and fills the 
core with tetrahedral elements.  The Cartesian method can be implemented with a body-fitted 
approach, with a global method, or with a hexa-core.  The Octree method was selected because 
it permits more flexibility for local refinement within ICEM than any of the other options.  The 
Octree method works by first encompassing the entire geometry with relatively large 
tetrahedral elements.  Then, the elements are subdivided into smaller and smaller volumes until 
all of the constraints are satisfied.  For example, it may stop when the minimum element size is 
reached, or when the local refinement parameters are met.  After subdivision, ICEM makes the 
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mesh conformal, and moves the nodes which are near the exterior of the volume to the surface.  
Lastly, it removes all of the elements not enclosed by the volume, and smooths the mesh.   
Picking the edge criterion is a tradeoff between the geometric accuracy of the mesh and the 
number of elements.  As shown in Figure 3-22, 50 microns was selected.  (The fact that the 
minimum element size is also 50 microns is merely coincidence.)  For more details on how this 
value was selected, refer to the Mesh Convergence Study.  The “Smooth Mesh” option is on by 
default, and was not altered.  The “Coarsen mesh” option is not on by default, but it was 
activated in an effort to further reduce element number.  Coarsening allows the mesh to be 
created with smaller elements which capture the geometry well.  Then, unnecessary refinement 
is removed to lower the element count.     
Finally, after defining all of the mesh settings, creating the mesh is as simple as pressing the 
“Compute Mesh” button.  Though, the mesh does require some additional scrutiny before it can 
be deemed acceptable.  Most importantly, excess materials need to be deleted prior to export. 
A created material (Figure 3-23) represents a free-floating volume that was not removed from 
the STL file, or a region of bone tissue that could not be connected by the elements.  For 
example, if two trabeculae were joined by a connection less than 50 microns thick, the meshing 
algorithm would be forced to create two separate parts.  Losing that connection may seem like a 
serious loss of fidelity, but it is not for two reasons.  First, the links never occurred between two 
large sections of the biopsy.  In all cases, the lost material was in an exterior region which would 
not have carried much (if any) load in the compression test.  Secondly, even if a more crucial 
connection were lost, it could not possibly have supported much load in comparison to the 
thicker trabeculae.  Figure 3-24 shows what the excess materials look like when the main body 
of the biopsy is hidden.   
Figure 3-23: ANSYS ICEM Materials 
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Figure 3-24: B02 Unattached Volumes in ICEM 
 
 ANSYS ICEM can perform a surfeit of mesh quality checks, but no check was performed on each 
individual biopsy.  A cursory visual inspection was completed, and if no problems were 
encountered during the analysis, it was assumed that the mesh quality was acceptable.  For 
reference, Figure 3-25 shows a mesh quality check from biopsy B02. 
Figure 3-25: Biopsy B02 Mesh Quality 
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Having verified its quality, the mesh must be exported to ANSYS APDL in order to run the finite 
element analysis.  The command for doing so is ‘File>Export Mesh>To Ansys’, which brings up 
the Solver window as shown in Figure 3-26.  Notice that no shell or bar elements are selected.  If 
they are included, as they are by default, the code in Appendix C will not run properly.    
Figure 3-26: ICEM Export Settings 
 3.6 ANSYS Compression Test 3.6.1 Software Selection 
Before describing the methodology used to perform analyses in ANSYS, it is worth discussing 
why the SCANCO FEA package was not selected.  The SCANCO software does possess a number 
of advantages: seamless integration with the scanned geometry, fast run times, use in 
numerous publications [59,60,61], and one-time pricing.   But, it is not nearly as convenient or 
versatile as ANSYS.  The SCANCO software is an addition to the company’s proprietary image 
42 
 
processing language.  A user performs the analysis by entering information into a command 
prompt. (FEA commands are on-screen in Figure 3-13.)  For anyone accustomed to the Windows 
environment, the software is unpleasant to use.  More importantly, it has severe technical 
limitations. The software can only analyze linear-elastic brick elements.   ANSYS, to the contrary, 
is a worldwide leader in finite element simulation.  ANSYS can handle, among other problems, 
material and geometric nonlinearities, stochastic analyses, multi-physics simulation, 
optimization, contact, composite materials, buckling, vibration, dynamic forces, and element 
death.  Secondarily, it has a vastly superior user interface.  The model manipulation and editing 
tools within ANSYS are easier to use, faster, and more capable than those in the SCANCO 
software.  As a final point, the ANSYS software has a wider user base, which makes learning the 
procedures and troubleshooting problems relatively easy.  3.6.2 Analysis Overview and Assumptions  
To evaluate the mechanical properties of the cancellous bone biopsies, they were put through a 
simulated 1% strain compression test.  This value is consistent with other compression tests 
found in the literature [62], although there is some variation.  Karim and Vashishth used 0.6% 
and 1.1% apparent-level strain for pre-yield and post-yield tests, respectively [63].  The values 
were chosen based on a yield point of   ̴0.8% for cancellous bone [64].  Since a linear elastic 
model was used in this research, the exact level of applied strain is not crucial.  The results can 
be scaled to any reasonable level of strain [65].   
The linear elastic model has been used in engineering analysis for decades [66], and pre-dates 
the finite element method [67].  The widely-used Euler-Bernoulli beam theory, which is 
responsible for many classic engineering equations, is based on a simplification of linear 
elasticity.  In order to apply the model to bone tissue, it is crucial that it satisfies the 
assumptions built into the model.  Those assumptions are that: 1) the material is linear, 2) no 
yielding occurs, and 3) strains remain small.   
To maintain material linearity the strain must be directly proportional to the applied stress.  
Most metallic materials are linear up to the yield point, after which they enter a region of 
nonlinear plastic behavior.  (Technically, there is a small nonlinear elastic region between the 
proportional limit and the yield point.) Certain materials, such as elastomers, concrete, and cast 
iron exhibit no linear behavior, even in the elastic region.  Multiple studies support the use a 
linear material model in human bone [68].  However, it should be kept in mind that fracture is a 
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post-yield event.  The linear model may be valid for calculating apparent-level young’s modulus, 
but the determination of fracture is complicated by nonlinear phenomenon.  For instance, 
bovine cortical bone exhibits non-linear material properties under dynamic loading [69].   
The requirement to avoid yielding is closely related to the linearity requirement, since the 
stress-strain curve is no longer a straight line after the yield point.  But unlike the linear 
assumption, which is primarily a matter of material property, satisfying the pre-yield assumption 
is a function of the geometry and the applied load.  Due do that fact, the assumption is violated 
for small portions of any given biopsy.  Thin trabeculae, in particular, are prone to exceeding the 
yield stress.  In a non-linear analysis is would be possible to remove the offending elements and 
iterate until there were no overly-stressed regions.  Since this is a linear analysis, the highly 
stressed elements were dealt with by using an accumulated-damage failure criterion.  
The third and final requirement is that strains remain small.  This is necessary because the small 
angle assumption was used in the derivation of the governing equations.  Most materials have 
small strain at yield, and bone is no exception.  Of all the linear elastic assumptions, this one is 
the most justifiable in regards to the present application.   
Isotropic material properties were used in the analysis, despite the fact that bone is known to be 
anisotropic [70,71,72].  Pistoia et al., using isotropic properties, achieved an R2=0.66 between 
FEA failure load and experimentally obtained failure load [65].  Finite element analysis has been 
performed on bone using anisotropic properties [73], but the application of directionally 
dependent properties would have been difficult given the geometric complexity of cancellous 
bone.      3.6.3 Detailed Procedure 
Now that the background assumptions are clear, the minutiae of the procedure itself will be 
specified.  Any finite element analysis can be divided into three fundamental steps: 
preprocessing, processing, and post-processing.  Preprocessing encompasses all the tasks 
necessary to set up the matrix equations.  Processing is the act of solving the set of algebraic 
equations.  Post-processing involves extracting desired information from the solution.  In this 
application, post-processing entails calculating stress and strain from the displacement field. 
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3.6.3.1 Preprocessing 
In an engineering analysis, the classic preprocessing steps are: 1) Geometry definition, 2) Mesh 
generation, 3) Application of material properties, and 4) Setting loads and boundary conditions.  
The first two steps are complete by the time ANSYS APDL is put into use.  The geometry is taken 
from the STL file obtained using microCT.  The meshing is done in ANSYS ICEM, and can be 
imported directly into APDL using the command ‘File>Read Input from’.  The default tetrahedral 
element type in ICEM is SOLID185, and that was not modified for this analysis.  SOLID 185 is an 
8-node element with 3 DOFS at each node.  The tetrahedral version is a degenerate element 
with 4 shared nodes at one vertex, and two shared nodes at a second vertex [74].   Generally, it 
is not recommended to have more than 10% tetrahedral elements in a model, but this rule was 
violated because tetrahedral elements excel at capturing the geometry of irregular surfaces.  
Any shortfall of the element was remedied by using a finer mesh.  The convergence study 
ensured that enough elements were used to obtain valid results.  Other tetrahedral elements 
were considered, such as the 10-node SOLID187, but were not selected due to the additional 
degrees of freedom required.   
After importing the mesh, material properties were defined.  The Young’s modulus of the bone 
tissue was set to 10 GPa, which is within the range of published values for cancellous bone [75].  
The poison’s ratio was set to 0.3.  Because a simple isotropic material model was used, no 
additional parameters had to be defined.  (Recall that of the shear modulus, Young’s modulus, 
and Poisson’s ratio, only two are independent.)  The left image in Figure 3-27 is biopsy B02 
directly after importing the ‘.in’ file created by ICEM.   
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Figure 3-27: Biopsy B02 Elements in ANSYS 
 
The boundary conditions were selected to simulate a 1% strain compression test.  In order to 
prevent rigid body motion, the nodes in the bottom 5% of the biopsy were fixed to zero 
displacement in all three directions.   To simulate the compression, the nodes in the top 5% of 
the biopsy were displaced until a 1% strain was achieved.  The right image of Figure 3-27 shows 
the applied boundary conditions, as well as the resulting reaction force. The 1% value was 
calculated from the portion of the biopsy without any applied boundary conditions.  For 
example, if a hypothetical biopsy was 10 mm long, the nodes in the top 0.5 mm would have 
been given a downward displacement of 0.09 mm.  Keep in mind, though, that the exact value 
of the displacement is not critical.  Because this is a linear analysis, the solution can be scaled to 
any value of applied compression.  If a 2% displacement were applied, then the stress at any 
point in the biopsy would be twice the value obtained from a 1% displacement analysis.   
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Admittedly, the applied boundary conditions are not particularly elegant.  The resulting stresses 
and strains in the top and bottom 5% of the biopsy are zero, so no useful information is 
extracted from those regions.  The methodology was implemented to accommodate biopsies 
with rough ends, and was never altered because—while crude—it is a valid compression test.   
3.6.3.2 Processing 
Selecting a solver is an often-overlooked part of the FEA process.  The majority of the time, the 
ANSYS default sparse solver works well.  When that is the case, solving requires no more effort 
than clicking a button.  However, as the total degrees of freedom increase, some consideration 
of the solver is justified.  Above 500,000 DOF, the Preconditioned Conjugate Gradient (PCG) 
solver becomes the more attractive option [76].  The PCG solver is iterative, and less robust than 
the sparse solver.  Nevertheless, it worked well in this application.   
3.6.3.3 Post-processing 
The direct output of any finite element model is simply a value for each degree of freedom at 
each node.  For SOLID185, the only degrees of freedom are displacements in the coordinate 
directions.  Using those nodal displacements combined with the interpolation functions, the 
result is a piecewise function describing the displacement at every point in the domain.  Using 
equations of linear elasticity on the function, stress and strain can be determined at any point.  
Specifically, the information extracted from each model included the reaction force, the energy 
equivalent strain, and the maximum von Mises stress.   
Figure 3-28 shows the displacement of B02 in two ways. The left image is an exaggerated display 
of the displacement, with the original shape outlined in white.  The image to the right is a 
counter plot based on the vector sum of displacement.  Unsurprisingly, the displacement is 
greatest at the top, and least at the bottom.  More interestingly, the displacement shows a clear 
relationship with the plates in the biopsy.   The von Misses stress is plotted in Figure 3-29, and it 
shows that the majority of the biopsy is lightly stressed.  A close-up on the right revels that small 
portions of the trabeculae are responsible for the high stresses.  So, much of the structure is 
under-utilized, at least for this one loading condition.  The finite element method can produce 
some exquisite-looking figures, but caution should be used in interpreting them.  Just because 
the results look good does not mean that they are accurate or pertinent.  The color contour plot, 
in particular, is subject to manipulation by altering the scale.  All of the plots presented here use 
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the ANSYS default scale, but readers should still be hesitant to make any conclusions based 
solely on the figures.     
Figure 3-28: Displacement 
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Figure 3-29: Von Mises Stress 
 
Rather than performing all of the pre/post-processing steps manually within the GUI, APDL code 
was written to automatically perform the analysis on each biopsy.  The full APDL code is in 
Appendix C. The code was derived from prior work by Vijayalakshmi Krishnaswamy and Dr. 
Rouch.  Three major upgrades were made to the original code.  First, there are no spring 
elements in the new code.  The old version required all of the elements to be connected by 
weak springs in order to prevent rigid body motion of rouge pieces unattached to the rest of 
model.  The extra elements were a detriment to solve times and memory requirements.  
Secondly, the updated code can process a list of ‘.in’ files without operator intervention.  
Thirdly, a cumulative strain-based failure criterion was added to the code.  
The code outputs the total y-direction reaction force, the maximum von Mises stress, the bone 
volume, the number of elements, the biopsy length, and the estimated failure load.  The bone 
volume and the biopsy length could have been determined in Netfabb from the STL geometry, 
but it was more convenient to obtain the values from the FEM.  The estimated failure load was 
based on the accumulated-strain criteria developed by Pistoia et al. [54].  In his experiments, the 
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force required for 2% of the bone volume to exceed an energy equivalent strain of 0.007 
showed the best correlation (R2=0.75) with experimentally measured fracture forces.    
To determine the failure load in this experiment, a table was created with element volumes and 
their corresponding strain.  The table was then sorted by strain.  Starting with the highest strain, 
the element volumes were added together one-by-one until the volume equaled 2% of the 
stressed volume.  (Due to the boundary conditions, 1.8% of the total volume was used in lieu of 
2% of the stressed volume.)  The single element which caused the summed volume to exceed 
the 2% mark was selected, and its strain value was scaled to 0.007.  Reaction force was scaled by 
the same factor to arrive at the failure load.  For example, if the 2% element had a strain of 
0.0035, the failure load was twice the reaction force.    3.7 Area Determination 
To ascertain the total biopsy volume and the unit failure load, the cross sectional area of the 
biopsies had to be measured.  If the same core drill had been used to extract the all of the 
biopsies, it would be reasonable to take the inner diameter of the drill as the cross sectional 
area.  As can be seen in Appendix E, the biopsies have a wide range of diameters.  There is no 
way to verify a drill size for each biopsy with certainty.  Further complicating matters, several 
biopsies were sliced approximately in half for previous studies requiring histological analysis.   
To determine the unique area of an individual biopsy, the nodal coordinates were exported to a 
text file from ANSYS APDL.  After plotting the points in 2 dimensions on the XZ plane, an 
intuitively clear picture of the biopsy cross section emerges.   
If only a handful of biopsies were being measured, it would be straightforward to manually 
connect the nodes around the perimeter and calculate an area.  In the interest of saving time, 
and eliminating any potential human bias, an automated method was employed.  As it turns out, 
the problem of encompassing a set of points with a polygon has already been studied 
extensively by mathematicians [77]. Or, more accurately, the smallest possible convex set 
containing given points has been studied.  A convex set is any set for which a line joining two 
points in the set lies entirely within the set (see Figure 3-30). 
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Figure 3-30: Convex Set 
 
The convex hull method will overestimate the existing cross section of the biopsies whenever 
there is reentrant geometry present.  However, the two nominal shapes which the biopsies 
should conform to, cylinders and half-cylinders, both have convex cross sections.  In fact, since 
the biopsies are extracted with a cylindrical drill, any reentrant portions of a biopsy should 
signify regions devoid of bone in the patient.  As such, the entire cross section, not just the 
portion containing bone, should be used when calculating total bone volume. 
Implementing the convex hull algorithm was done within MATLAB R2012a.  What minimal code 
was necessary was developed in cooperation with Jonathan Ward, and can be found in 
Appendix D.  As with the ANSYS APDL code, the biopsies were run in a batch mode.  The nodal 
points and convex hull outline are shown in Figure 3-31.    
NOT CONVEX 
     
CONVEX 
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Figure 3-31: Biopsy B04 Outline 
 
Admittedly, the method described above does not always produce a perfect cross section.  
Occasionally the cut plane in the biopsy is not well aligned with the axis of the original cylindrical 
biopsy, in which case the resulting shape is not prismatic.  Any misalignment of the biopsy will 
skew the cross section, as will any misshapen portion jutting out from the main body.  In these 
cases, the convex hull algorithm will slightly overestimate the cross sectional area.  However, 
these are primarily issues of biopsy quality, and they do not reflect on the area measurement 
method.   With diligent biopsy preparation, the potential for error is small.   3.8 Calculated Properties 
No direct comparison can be made between biopsies after the finite element analysis because 
stiffness varies as a function of cross sectional area.  Similarly, the reaction force must be 
converted into an equivalent stress before any comparison is meaningful.  The equations in this 
section describe precisely how the values in the results section are calculated.  The overall 
philosophy of the calculations is to treat the bone biopsy as a single homogeneous material.  
With that assumption, material properties for the total bone are derived.   
The stiffness of bone is correlated to fracture [78], so it may show a correlation with long term 
bisphosphonate use.    
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𝜖
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𝐹𝑟 = 𝐹𝐸𝐴 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑓𝑜𝑟𝑐𝑒 
𝐴 = 𝐴𝑟𝑒𝑎 
The apparent modulus as calculated above makes no correction for the amount of cancellous 
bone tissue in the biopsy.  Looking only at the Young’s modulus there is no way to determine 
what portion is due to good microarchitecture, and what portion is due simply to a large amount 
of trabecular tissue.  If two biopsies were to have the same modulus, yet one biopsy achieved 
the value at a lower BV/TV ratio, then it must have superior architecture. 
𝐸𝑒𝑓𝑓 = 𝐸 ∗ 𝑇𝑉𝐵𝑉  [𝑁 𝑚𝑚2⁄ ] 
𝑇𝑉 = 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 
𝐵𝑉 = 𝑏𝑜𝑛𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 
While stiffness is of some value, it does not predict failure.  Many failure criteria exist, even 
when considering only isotropic materials.  When analyzing metallic structures, failure is 
commonly defined based on the von Mises stress.  Since it condenses the full three dimensional 
stress state of the material into a single value, the von Mises stress is also an incredibly 
convenient criterion.  Nonetheless, it still requires modification before biopsies can be 
compared.  The von Mises stress resulting from the compression test is misleading because the 
reaction force required to achieve the 1% strain is not consistent.   So, a stress amplification 
ratio (SAR) was calculated. 
𝑆𝐴𝑅 = 𝜎𝑚𝑎𝑥
𝜎𝑟
= 𝜎𝑚𝑎𝑥
𝐹𝑟 𝐴⁄
 
𝜎𝑟 = 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑠𝑡𝑟𝑒𝑠𝑠 
𝜎𝑚𝑎𝑥 = 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑣𝑜𝑛 𝑀𝑖𝑠𝑒𝑠 𝑠𝑡𝑟𝑒𝑠𝑠 
The von Mises failure criterion assumes that the entire structure fails when any portion of the 
structure—however small—exceeds the material allowable stress.  In order to allow for 
accumulated local damage prior to global failure, a strain-based method was utilized.   
  
𝜎𝑓𝑔 = 𝑓𝑓𝑔𝐴  
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The failure load originating from the finite element analysis was simply divided by the cross 
sectional area for fair comparison.  The result, on the apparent level, is a failure stress.   
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4 Results  4.1 Coarse Mesh Output 
All 30 biopsies were initially modeled with a relatively low number of elements.  The meshes 
were created using the auto-sizing option in ANSYS ICEM, which selects a seed element size of 
0.025 times the bounding box diagonal of the geometry.  The edge criterion was modified to 
0.01 mm.  All other ICEM settings were left on their default values.  This method created meshes 
ranging from 25,258 (B04) to 133,190 elements (B11).  The large range in the number of 
elements is chiefly attributable to the variation in bone volume, which spanned from 1.7 mm3 
(B19) to 48.8 mm3 (B24).  The biopsies with the extreme volumes did not correspond to those 
with the extreme number of elements due to differences in microarchitecture.   
The auto-sized mesh resulted in elements which were too large to represent the detailed 
geometry of the biopsies.  The seed element size was for B02 was 0.2 mm.  Since the trabeculae 
were typically around 0.150 mm, and sometimes as small as 0.050 mm, the seed element size 
was too large to capture the geometry accurately.  For reference, the zoomed-in portion of the 
biopsy in Figure 4-1 is about 70 microns in diameter.  Evidently, some elements are created 
below the seed size, but not enough to give good results.    
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Figure 4-1: Biopsy B02 Coarse Mesh 
                                          
Despite the known fact that the coarse mesh did not represent the bone geometry well, it still 
presented a number of advantages.  Principally, the ANSYS license available at the University of 
Kentucky prior to July 2012—the academic teaching license—is only valid for processing models 
under 250,000 elements.  The lower density models served as an interim object of study until 
higher fidelity meshes could be analyzed.  Secondarily, the smaller models had much faster solve 
times.  The entire process of generating the matrix, solving, and calculating element results took 
less than a single minute per biopsy.  Without the burden of lengthy run times, many iterations 
of the APDL code could be tested.  After developing working code on the coarse meshes, 
applying it to the fine meshes was effortless.  But, the coarse mesh was not just a tool to 
troubleshoot code and get around an element number limitation.   
Studies done by a prior student, Vijayalakshmi Krishnaswamy, showed that significant results 
could be acquired with a coarse mesh.  P-values less than 0.05 were obtained between groups 
(n=10) of low-turnover stage five CKD patients and normal-turnover patients without CKD.  The 
result was expected based on how drastically different the two groups were.   
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Unfortunately, unlike in the CKD study, no statistically significant results were found between 
the three experimental groups in this research.  For each of the calculated properties, a one-way 
ANOVA was used to gauge significance.  For reference only, the ANOVA was followed up with an 
unpaired two-tailed Welch-corrected t-test on each set of experimental groups.  (For more 
details on why this test was chosen, refer to the Statistical Analysis.)   
Table 4-1: Coarse Mesh Results Summary 
Mean ± SD Control Short Term Long Term 
E [MPa] 320±352 617±898 244±218 
Eeff [MPa] 1890±1566 2076±1871 1437±691 
SAR 503±371 634±1144 647±752 
σult [MPa] 1.84±1.54 3.11±3.76 1.63±1.07 
 
Table 4-2: Coarse Mesh P-Values 
 
ANOVA Control vs. Short Control vs. Long Short vs. Long 
E [MPa] 0.3204 0.3519 0.5712 0.2315 
Eeff [MPa] 0.6103 0.8123 0.4197 0.3332 
SAR 0.9104 0.7381 0.5971 0.9765 
σult [MPa] 0.3479 0.3418 0.7296 0.2575 
 
Since no significance was found, there was substantial motivation to increase the mesh density.  
Decreasing element size simultaneously improves the geometrical representation of the 
biopsies, and refines the solution of the governing differential equations.  It was hoped that the 
increased precision of the finite element model would decrease the standard deviation of the 
groups, allowing for more statistical power.   4.2 Mesh Convergence Study 
Since it was concluded that the coarse mesh could not accurately model the geometry of the 
biopsies, the mesh density was increased.  Increasing the element number increases the 
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computational requirements, so the ICEM mesh settings were studied to find the optimal 
parameters.    4.2.1 Global Element Size 
The first variable examined was the global maximum element size, which also serves as the seed 
element size.  Values ranging from 65 µm to 250 µm were tested; the results are reported in 
Table 4-3.  As only one biopsy (B09) was used to create all of the meshes, it was not necessary to 
account for the cross sectional area.   The reaction force, Fy, was reduced by 4.75% going from a 
seed size of 75 µm to 65 µm.  That level of change is undesirable, but the element number could 
not be increased further due to computational limitations.  In an attempt to achieve tighter 
convergence at a lower element number, local refinement was enabled. 
Table 4-3: Effect of Global Max Element Size 
Size [µm] Fy [N] σmax [MPa] BV [mm3] Elem # 
65 5.21 2691.3 8.08 718310 
75 5.47 1619.7 8.04 521680 
100 6.07 2107.1 7.96 277940 
125 6.48 1502.0 7.87 171430 
150 6.91 935.5 7.78 118450 
250 (auto) 7.79 438.6 7.58 47872 
 4.2.2 Local Refinement: Minimum Element Size 
Local refinement allows the element size to be smaller where the geometry dictates the need 
for it, and larger in less complex regions.  When using this method, the global element size was 
left at 250 µm, which is the size chosen by ICEM if running with auto-sizing enabled.  The 
refinement parameters: elements in gap, and curvature refinement, were held constant at 1 and 
10, respectively, throughout the analysis.  The only variable altered between each run was the 
minimum element size.  As in the global element test, the smallest size attempted was 65 µm.  
In the transition from a 75 micron limit to a 65 micron limit, the reaction force fell by 3.56%, 
while the element number increased 25.9%.  Compared to decreasing global max element size, 
local refinement achieves a tighter convergence at a lower element number.  At the 65 µm level, 
the uniform-element mesh had 21.3% more elements than the locally-adjusted mesh.  Despite 
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the clear improvement, other mesh settings were investigated to achieve a more efficient 
model.   
Table 4-4: Reducing Minimum Element Size 
Size [µm] Fy [N] σmax [MPa] BV [mm3] Elem # 
65 5.48 2528.0 8.07 592240 
75 5.61 2031.6 8.04 470290 
100 6.05 1039.9 7.95 271260 
125 6.49 991.4 7.87 170280 
150 6.91 935.5 7.78 118450 
 4.2.3 Setting Edge Criterion to 200 Microns 
The previous two studies used an edge criterion (EC) of 0.01 mm.  The edge criterion defaults to 
a value of 0.2 mm, but it was changed at the onset of this research to 10 microns.  The value was 
chosen with the SCANCO voxel size of 30 microns in mind.   Concerned that an edge criterion of 
0.01 mm may be too severe, the local refinement study was performed again, with the criterion 
increased back to its default setting.  Notice that, for the same level of refinement, the reaction 
force from the strict EC is nearly identical to that from the relaxed EC.  At 65 µm, the difference 
is only 0.36%.  However, the relaxed EC offers a significant advantage in element number.  In the 
range from 100 µm down to 65 µm, increasing the EC decreased the element number by an 
average of 50.1%.   
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Table 4-5: Edge Criterion = 0.2mm 
Size [µm] Fy [N] σmax [MPa] BV [mm3] Elem # 
40 5.32 1559.4 8.09 649420 
50 5.36 1139.2 8.07 523390 
65 5.50 1393.5 8.01 331620 
75 5.56 579.5 7.96 242550 
100 6.06 469.6 7.84 113930 
125 6.77 479.8 7.73 61847 
150 7.41 421.5 7.62 39847 
4.2.4 Edge Criterion as the Independent Variable 
Not satisfied with simply resorting back to the default edge criterion, an additional study was 
performed to determine if the edge criterion could be decreased below 0.2 mm without 
adversely increasing element number.  Using a local element size limit of 65 µm, the EC was 
varied from 10 to 200 microns.  As shown in Table 4-6, there is no consistent trend between the 
edge criterion and the reaction force.  But, biopsy volume trends higher as the EC decreases, 
which is a sign that the geometry of the STL is being captured in more detail.  As a compromise 
between geometric accuracy and element number, 50 microns was selected for the final mesh.  
Table 4-6: Altering Edge Criterion 
EC [µm] Fy [N] σmax [MPa] BV [mm3] Elem # 
10 5.48 2528.0 8.07 592240 
25 5.46 2275.9 8.05 472940 
50 5.47 2103.0 8.04 382280 
100 5.50 1703.3 8.02 344630 
150 5.48 1293.2 8.01 334590 
200 5.50 1393.5 8.01 331620 
 4.2.5 Mesh Coarsening 
Before arriving at the final settings to create the detailed mesh, mesh coarsening was 
investigated.  Mesh coarsening works by first meshing with small elements to capture the 
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geometry, and then remeshing the interior with larger elements.   In order to compare the 
results to the minimum element size study, the EC was set to 0.01 mm and a maximum element 
size of 0.25 mm was used.  Two iterations of mesh coarsening were performed, with the worst 
allowable aspect ratio equal to 0.2.  As before, minimum element size was the independent 
variable.  For a minimum size of 65 µm, the coarsening algorithm only reduced the number of 
elements by 3.4%.   
Table 4-7: Mesh Coarsening 
Size [µm] Fy [N] σmax [MPa] BV [mm3] Elem # 
50 5.44 1543.9 8.11 776480 
65 5.52 2526.0 8.07 572000 
75 5.63 2029.6 8.04 461430 
100 6.05 1047.4 7.95 269150 
125 6.49 990.3 7.87 169940 
150 6.92 939.8 7.78 118270 
 4.2.6 Combined Settings 
Local refinement, a relaxed edge criterion, and mesh coarsening all decreased element number 
while preserving model fidelity.  In order to minimize the element number further still, all three 
techniques were applied simultaneously.  An edge criterion of 50 microns was used.  The mesh 
coarsening parameters were unchanged from those described previously, and the minimum 
element size was used as the independent variable.  Combining all of the mesh refinement 
methods resulted in a faster convergence than any individual technique, at the lowest element 
number.  Decreasing the minimum size to 40 microns only altered the reaction force by 0.38%, 
but increased the number of elements by 21.9%.  Because the 40 micron minimum provided 
little benefit, a minimum size of 50 microns was used to mesh the remaining 30 biopsies.     
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Table 4-8: Combined Settings 
Size [µm] Fy [N] σmax [MPa] BV [mm3] Elem # Fult 
40 5.52 1563.1 8.10 493420 5.720 
50 5.54 869.1 8.09 404590 5.711 
65 5.73 1561.2 8.04 288770 5.805 
75 5.81 1715.4 7.99 234100 5.859 
100 6.14 1315.0 7.89 142520 6.019 
125 6.59 1201.1 7.81 92320 6.201 
150 7.10 780.7 7.74 66809 6.447 
 4.2.7 Comparison of all Meshing Methods  
The various meshing methods do not appear to converge to a single value, but they all level out 
around 5.5 newtons.  Because of the large variation between the biopsies, the small difference 
between the methods is not expected to be a concern.  The difference between the two most 
divergent methods at approximately 750,000 elements is only 4.3%.   
Figure 4-2: Reaction Force Response to Meshing Method 
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If the geometry were not affected by the meshing method, then one would expect to see the 
maximum von misses stress converge to a single value.  For example, if a simple rectangular 
beam were being analyzed, the geometry could be captured perfectly with very few elements.  
In such a simplified case, mesh refinement would alter the solution, but not the geometry.  The 
geometry of the cancellous bone biopsy is comparatively complex, and the geometry changes 
slightly in response to the mesh density.  (Since the tetrahedral elements used have straight 
sides, they will never capture the true curvature of the domain.)  Consequently, the maximum 
von Mises stress did not converge as reaction force did.  The trend is generally upwards, but 
there are numerous counterexamples in Figure 4-3. The upward trend is likely caused by stress 
concentrations in the biopsy geometry.  With a high stress gradient, smaller elements are less 
likely to span a region of both high and low stress.  Instead, they lie entirely within a highly 
stressed region.     
Figure 4-3: Maximum Von Mises Stress vs. Element # 
 
In all cases, increasing the element number increased the bone volume represented in the 
mesh.  The combined methodology arrives at roughly the same volume (8.10 mm3) as the other 
methods, but at a much lower number of elements.   
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Figure 4-4: Bone Volume vs. Element # 
 
On account of the fact that the von Mises stress had poor convergence, a more reliable failure 
criterion was needed.  Using the combined mesh settings, the accumulated strain based failure 
method was investigated.  The results in Table 4-8 show much better convergence than the von 
Mises stress.  This is logical, because the accumulated damage model is not sensitive to peak 
values of stress or strain.  The steep stress gradients alter peak element values of stress, but 
they do not change the volume of highly stressed elements.   The slight upturn, apparent in 
Figure 4-5, was unexpected but it is not disconcerting.    
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Figure 4-5: Strain-Based Failure Load vs. Element # 
 
 The fine mesh is visibly superior to the coarse mesh.  Figure 4-6 shows the old coarse mesh on 
the left, and the fine mesh on the right.  It is clear that the fine mesh better represents the 
magnified region, but there is still room for improvement.  Nevertheless, convergence was 
achieved for reaction force, so additional detail in regions that small must not appreciably affect 
the results.  Using smaller elements in future studies could give better convergence of the von 
Mises stress.   
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Figure 4-6: Coarse-Fine Mesh Comparison 
  4.3 Fine Mesh Result 
Switching from the coarse mesh to the fine mesh, element number increased, on average, by a 
factor of 10.57. The two largest biopsies by volume, B14 and B24, used slightly different mesh 
parameters in order to stay within computational limits. The maximum element size used was 
0.35 mm, the minimum element size was 0.06 mm, and the edge criterion was 0.1 mm.  The 
smallest model (B055-07) contained 130,930 elements, and the largest (B060-03) was comprised 
of just over 1.14 million elements.   As expected from the convergence study, most of the 
biopsies had a lower reaction force when analyzed with a higher element density.  Two biopsies 
did buck the trend, however, as Figure 4-7 illuminates.  The reduction in reaction force never 
exceeded 17%.  Other properties, such as the modulus of elasticity, had a larger response to 
element number.    
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Figure 4-7: Failure Load Response to Mesh Density 
 
Figure 4-8: Modulus Response to Mesh Density 
 
The fine mesh did not have the desired effect of decreasing the standard deviation.  The raw 
data in the form mean±SD is reported in Table 4-9, and coefficient of variation (CV) is compared 
to the coarse mesh in Table 4-10. For all but the stress amplification ratio, the CV of the fine 
mesh either increased or was nearly stagnant.   
-20
-15
-10
-5
0
5
10
1 6 11 16 21 26
Pe
rc
en
t C
ha
ng
e 
(%
) 
Biopsy Number 
Failure Load Response to Mesh Density 
-35
-30
-25
-20
-15
-10
-5
0
1 6 11 16 21 26
Pe
rc
en
t C
ha
ng
e 
(%
) 
Biopsy Number 
Modulus Response to Mesh Method 
67 
 
Table 4-9: Fine Mesh Data 
Mean ± SD Control Short Term Long Term 
E [MPa] 284.8±324.4 517.0±769.0 200.1±184.5 
Eeff [MPa] 1574.9±1448.8 1663.6±1596.3 1099.0±599.0 
SAR 914.1±834.6 1092.3±1823.3 1159.5±1061.7 
σult [MPa] 1.75±1.46 2.81±3.35 1.48±0.96 
 
Table 4-10: CV for Coarse and Fine Mesh 
Coefficient of Variation 
E [MPa] 
Coarse 1.100 1.457 0.894 
Fine 1.139 1.487 0.922 
Eeff [MPa] 
Coarse 0.829 0.901 0.481 
Fine 0.920 0.960 0.545 
SAR 
Coarse 0.738 1.805 1.163 
Fine 0.913 1.669 0.916 
σult [MPa] 
Coarse 0.836 1.207 0.656 
Fine 0.832 1.191 0.645 
 
Table 4-11: Fine Mesh P-Values 
 
ANOVA Control vs. Short Control vs. Long Short Vs. Long 
E [MPa] 0.3454 0.3962 0.4846 0.2337 
Eeff [MPa] 0.5819 0.898 0.3577 0.3175 
SAR 0.9109 0.7835 0.5732 0.9212 
σult [MPa] 0.3665 0.3763 0.6312 0.2548 
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Despite the fact that the refined meshing procedure altered the biopsy properties by a 
substantial amount, it was not enough to improve the statistical significance between the 
experimental groups.  A look back at Table 4-2 proves that the p-values are scarcely different.  4.3.1 Regression Analysis 
In addition to calculating p-values to test for significance between groups, the results were 
analyzed directly against bisphosphonate duration.   The separation between short and long 
term use was admittedly somewhat arbitrary, and it is possible that the decision obscured the 
true effect of the drug.    Unfortunately, the outcome was still not statistically significant.  The 
highest R2 value, occurring between the effective modulus and treatment duration, was an 
abysmal 0.0163.   
Figure 4-9: Modulus vs. Bis. Duration 
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Figure 4-10: Effective Modulus vs. Bis. Duration 
 
The largest modulus occurred in B21, which had the highest BV/TV ratio (0.47) in the study.  It 
also had the highest effective modulus, but B26 came close by virtue of its lower BV/TV ratio 
(0.20).   
Figure 4-11: Failure Stress vs. Bis. Duration 
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Figure 4-12: Stress Amplification vs. Bis. Duration 
 
The failure stress and stress amplification ratio show no discernible relationship with 
bisphosphonate duration.  The largest SAR occurred in B19, which had the lowest BV/TV ratio is 
the study (0.06).    4.4 Statistical Analysis 
The basis of most statistical methods is the normal distribution of data.  The primary reason for 
the assumption is that many natural phenomena are a close fit to the Gaussian distribution.  
Though, since the distribution ranges infinitely in each direction, a perfect fit is rare.  For 
example, a normal distribution applied to this experiment’s data would predict the existence of 
some biopsies with negative strength.  In practice, one would not expect to encounter a biopsy 
with negative strength, regardless of the sample size.  Another reason for the normal 
distribution’s ubiquitous use is its ability to be conveniently expressed as an exponential 
function. 
𝑓 = 1
𝜎√2𝜋 𝑒12�𝑥−𝜇𝜎 �2  
So, it is justifiable to assume the experimental data follows a normal distribution? Most of the 
groups failed a Kolmogorov–Smirnov test with a p-value of less than 0.10, which would indicate 
the data is not normally distributed.  Typically, transforming data by taking the inverse or the log 
can convert it to a normal distribution.  After taking the log of the fine-mesh failure load data, it 
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passed the K-S normality test. However, it had the adverse effect of increasing the p-value from   
0.3665 to 0.9290.  Taking the inverse of the data did help the normality, but one group still 
failed the K-S test.  The resulting p-value was once again elevated (p=0.5449).   
Even with untransformed data, there may be reason to believe that statistical tests based on a 
normal distribution can be used. The number of biopsies in each group is only 10.  For a sample 
size that small, the K-S test is not powerful enough to reliably determine the distribution of the 
entire population [79].  Discounting the K-S test, it is necessary to fall back on general statistical 
principals.  The distribution of the entire population is what dictates the applicability of 
statistical tests, so any evidence of normality in the population will override indications to the 
contrary in the specific subset collected for this experiment.  Unfortunately, bone strength in 
broiler chickens has been shown to have a log-normal distribution [80].  Experiments in humans 
have also encountered non-normal distributions [81], sometimes even after transformation 
[82].  The lack of normality is expected because the variation is due to a large number of 
interrelated, not independent, variables.     
The motivation behind using a normal distribution is the ability to use parametric tests.  Non-
parametric tests do not assume any distribution, but are not as powerful as parametric tests.  
That is to say, they are more likely to ‘fail to reject’ a false null hypothesis (a type II error).   On 
the other hand, if a parametric test is used on non-normal data, the chance of committing a 
type I error is increased.  But, if none of the experimental data comes out to be statistically 
significant, there is no reason to worry about type I errors.  For that reason, a normal 
distribution is used throughout this research for matters of convenience.  In the event that any 
significant result is found, it will be scrutinized with more rigorous methods.    
Even when assuming a normal distribution, no statistical significance was found between the 
three experimental groups.  Looking at Figure 4-9 through Figure 4-12, it is apparent that the 
data is extremely scattered.  In order to see a significant difference, either the standard 
deviation must be reduced, or more biopsies need to be analyzed.  Unfortunately, more biopsies 
cannot be included from the biopsy bank without altering the inclusion criteria.  However, 
decreasing the standard deviation can be accomplished by removing outliers.   
The method chosen to identify outliers was Chauvenet's criterion, which states that a data point 
may be removed if the probability of obtaining it is less than 1/(2*N).  For example, if 10 
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readings were collected, those with a probability of less than 5% can be discarded.  For a normal 
distribution, 95.4% of data lies within two standard deviations.  So, with a sample size of 10, 
Chauvenet's criterion rejects any point more than 2 standard deviations from the mean.  
Rejecting outliers from each group individually would have resulted in discarding many data 
points.  To be slightly more conservative, outliers were only rejected based on the data from all 
30 biopsies.  The test was performed based on apparent modulus, effective modulus, SAR, and 
failure load.  At a sample size of 30, data is rejected when it is more than 2.394 standard 
deviations from the mean.  When a biopsy was rejected as an outlier based on one parameter, it 
was removed from the study entirely.  For example the SAR for B19 was officially rejected as an 
outlier.  Even though the modulus and failure load for B19 were not rejected based on 
Chauvenet's criterion, those data points were removed from the calculations.  The idea is that 
the biopsy itself is an outlier, not just one piece of data derived from it.     
Chauvenet's criterion identified B21, B26, and B19 as outliers.  Biopsy B21 was rejected based 
on apparent modulus, effective modulus, and failure load.  It had a BV/TV of 0.47, which was the 
highest ratio in the study.  It is abnormal for cancellous bone to have such a high ratio, so there 
was solid ground to reject the biopsy.  B26 had the second highest effective modulus.  Unlike 
B21, it had a reasonable BV/TV of 0.20. Referring to Appendix E, the microarchitecture of the 
biopsy stands out.  Based on its exceptionally plate-like form, it was rejected without hesitation.  
Lastly, B19 was rejected due to its large stress amplification ratio.  Because SAR showed poor 
converge, more evidence was needed to comfortably reject it.  The biopsy did have the lowest 
BV/TV ratio in the study (0.06), but more damaging was its poor connectivity.  From Figure 4-14 
it is evident that the top of the biopsy is only connected to the bottom portion by one trabecula.  
With the entire load traveling through such a small portion of the biopsy, the results are 
completely invalid.  The von Mises stress, in Figure 4-13, peaks in a highly localized region of the 
biopsy.   
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Figure 4-13: Von Mises Stress in B19 
 
Figure 4-14: Displacement of B19 
 
Biopsy B26 was in the control group, and the other two outliers were in the short-term group.  
The revised data is presented in Table 4-12, along with the unchanged long-term data.  
Naturally, the standard deviations for the altered groups are much lower than those of the 
original groups (Table 4-9).  However, the change was not enough to produce any significance, 
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as shown in Table 4-13. In fact, some p-values increased because the difference between the 
means decreased.  
Table 4-12: Fine Mesh Data sans Outliers 
Mean ± SD Control Short Term Long Term 
E [MPa] 203.9±211.4 340.4±394.4 200.1±184.5 
Eeff [MPa] 1188.4±825.3 1430.9±1041.5 1099.0±599.0 
SAR 1004.2±832.1 583.9±432.1 1159.5±1061.7 
σult [MPa] 1.42±1.07 2.12±1.75 1.48±0.96 
   
Table 4-13: Fine Mesh P-Values sans Outliers 
 
ANOVA Control vs. Short Control vs. Long Short Vs. Long 
E [MPa] 0.4874 0.4025 0.9675 0.3773 
Eeff [MPa] 0.6906 0.6806 0.7928 0.4415 
SAR 0.3546 0.2091 0.7261 0.1446 
σult [MPa] 0.4648 0.3448 0.8941 0.3738 4.5 Fixed-Length Finite Element Analysis 
In a final attempt to decrease the variability of the data, the biopsies were analyzed at a fixed 
length.  After removing the cortical bone, the length of the biopsies ranged from 4.56 mm to 
16.21 mm.  The inconsistency in length was not thought to be an issue because a constant strain 
was applied.  However, it is conceivable that the length confounded the results.  For example, a 
long biopsy would be more likely to contain a weak region than a short biopsy, even if both were 
taken from two identical bones.  Consider the analogy of a chain composed of many links.  If the 
individual link strengths are normally distributed, and the chain strength is dictated by the 
weakest link, then the mean strength of longer chains will be less than that of short chains.  The 
principle has been applied to spun yarn [83], and could arguably be extended to compressive 
strength of materials with microarchitecture.  
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 The analyzed length was set to be slightly less than the shortest biopsy:  4 mm.  This value was 
chosen to maximize the volume of bone analyzed, while still ensuring that all of the biopsies had 
some material removed from each end.  As well as giving all biopsies an equal probability of 
containing a weak region, fixing the analyzed volume to a set length had two secondary 
benefits.  First, by analyzing the central portion of each biopsy, any remnants of cortical bone 
that may have been included in the initial analyzes were removed.  Second, the decreased bone 
volume allowed biopsies B14 and B24 to be analyzed without relaxing the meshing parameters.   
Table 4-14: Fixed-Length Data 
Mean ± SD Control Short Term Long Term 
E [MPa] 331.4±374.4 682.2±837.1 239.5±196.3 
Eeff [MPa] 1994.1±1807.1 2333.8±1877.6 1458.1±658.0 
SAR 701.8±665.2 889.5±1890.2 621.5±687.9 
σult [MPa] 1.93±1.69 3.60±3.93 1.61±0.96 
 
Table 4-15: CV for Fixed and Original Length Analyses 
Coefficient of Variation 
E [MPa] 
Fixed L. 1.130 1.227 0.820 
Orig. L. 1.139 1.487 0.922 
Eeff [MPa] 
Fixed L. 0.906 0.804 0.451 
Orig. L. 0.920 0.960 0.545 
SAR 
Fixed L. 0.948 2.125 1.107 
Orig. L. 0.913 1.669 0.916 
σult [MPa] 
Fixed L. 0.875 1.092 0.596 
Orig. L. 0.832 1.191 0.645 
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Table 4-16: Fixed-Length P-Values 
 
ANOVA Control vs. Short Control vs. Long Short Vs. Long 
E [MPa] 0.1748 0.2496 0.5041 0.1379 
Eeff [MPa] 0.4556 0.4123 0.397 0.1914 
SAR 0.8818 0.7726 0.7941 0.6817 
σult [MPa] 0.1892 0.2421 0.6103 0.1517 
 
The fixed-length analysis had coefficients of variation similar to the original-length analysis, yet 
the ANOVA p-value was reduced in every category.  The failure load p-value was reduced from 
0.3665 to 0.1892.  Of course, that is still well above any commonly-used significance threshold. 
Unlike increasing the mesh density, which had a unilateral effect on the failure load and 
modulus, reducing the region of analysis had a more bidirectional influence.  The magnitude of 
the change was also far greater than when modifying mesh density.  The greatest change in 
failure load going from the coarse mesh to the fine mesh was -16.15%, but the largest change 
when switching to the 4-mm analysis was 106.08%.  The apparent modulus (Figure 4-16) 
experienced even greater alteration: 190.5%.   
Figure 4-15: Effect of Reduced Length on Failure Load 
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Figure 4-16: Effect of Reduced Length on Apparent Modulus 
 
Figure 4-17: Effect of Reduced Length on BV/TV Ratio 
 
The percent increase in failure load and apparent modulus show a slightly upward trend with 
original biopsy length.  This justifies the rationale behind performing the fixed-length analysis in 
the first place.  The BV/TV ratio, in Figure 4-17, exhibits a surprising amount of variation.  If the 
amount of cross sectional area being analyzed was enough to represent the cancellous bone, 
less disparity in BV/TV would be expected.  The small analyzed bone volume could be 
responsible for the lack of significance.   
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Chauvenet's criterion was applied to the fixed-length data, and 4 biopsies were removed.  Three 
of the biopsies were the same ones rejected during the original-length analysis.  The newly 
discarded biopsy (B24) was rejected based on apparent modulus and failure load.  It had the 
second highest BV/TV ratio in the study (0.375).  More importantly, it has a streak of cortical 
bone down its right-hand side as shown in Figure.        
Table 4-17: Fixed-Length Data sans Outliers 
Mean ± SD Control Short Term Long Term 
E [MPa] 235.4±232.7 351.9±281.0 239.5±196.3 
Eeff [MPa] 1492.6±918.9 1780.8±915.4 1458.1±658.0 
SAR 771.5±665.7 361.9±314.5 621.5±687.9 
σult [MPa] 1.53±1.16 2.08±1.21 1.61±0.96 
 
Table 4-18: Fixed-Length P-Values sans Outliers 
 
ANOVA Control vs. Short Control vs. Long Short Vs. Long 
E [MPa] 0.55 0.3949 0.9678 0.3826 
Eeff [MPa] 0.7041 0.5436 0.9272 0.4427 
SAR 0.4159 0.1321 0.636 0.314 
σult [MPa] 0.5791 0.3734 0.8616 0.414 
 
With the exception of SAR, all of the p-values increased after removing the outliers.  Just as 
when outliers were removed from the original-length analysis, the movement of the means 
counteracted the decreased standard deviations.    
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5 Discussion 5.1 Determination on the Use of Bisphosphonates 
Based solely on the data collected, the null hypothesis could not be rejected.  However, that 
does not conclusively mean that the null hypothesis is true.  Ultimately, no confident decision 
can be made about the long-term efficacy of bisphosphonates from this research.  The problem 
lies in the fact that the statistical power of the test was quite low.  (The probability of rejecting a 
false null hypothesis is statistical power.)  G*Power v3.1.5 software was used to assess the 
power of the experimental data post-hoc with α=0.05.  For simplicity, only the failure load in the 
fixed-length analysis is considered here.  Comparing the short and long-term groups, the power 
is 31.3% (effect size=0.6956).  That means the probability of committing a type II error is 68.7%. 
In order to have a power of 80% with the same alpha and effect size, 34 biopsies would be 
needed in each group.  Moreover, the case just presented had one of the lowest p-values of any 
t-test in this research.  Looking at a more representative match-up, like the one between the 
control group and the long term group, the power is only 7.8% (effect size=0.233).  For that 
effect level, 291 biopsies would be needed in each group to have 80% power.  
While the data obtained from the iliac crest biopsies did not show significance, it does match up 
well with published properties for cancellous bone.  Based on physical tests of 48 cylindrical 
(ø=8mm, L=25mm) cancellous bone specimens, Kopperdahl and Keaveny found that the 
compressive modulus ranged from 100 to 500 MPa [90].  The stress at yield varied from 0.5 to 
3.6 MPa.  The median apparent modulus of all 30 biopsies in this study was 212.6 MPa; the 
median failure load was 1.46 MPa.  So, the data collected is centered about well-established 
properties for human cancellous bone.   
The range of the data, however, was greater than that observed by Kopperdahl’s research.  The 
disparity may be attributed to his exclusive use of low-density (0.18 +/- 0.04 b/cm3) specimens, 
or a difference in anatomical site between the two studies.  Cohen et al, found that the FEA-
derived modulus of trabecular bone from transiliac biopsies (n=54) was 660±485MPa [85].  His 
range was 79-2165 MPa, compared to 1.6-2430 MPa in this research.   5.2 Sources of Variation 
No research is perfect, particularly in the medical field where experimental design must take a 
back seat to ethical considerations.  It simply is not practical to control every possible variable.   
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For instance, dictating exercise levels, calcium intake, and ethanol use was not feasible in this 
study.  As the sample size increases the law of large numbers takes over, and the uncontrollable 
variables—assuming they are independent—should have an equal effect on each experimental 
group.  Unfortunately, it was not possible to increase sample size while maintaining age-
matched low-turnover groups.  Aside from the small sample size, the power may have been 
reduced by inadequate biopsy dimensions, lack of control over biopsy orientation, deviation in 
biopsy location, and sub-optimal geometry capture. 5.2.1 Biopsy Size 
The high variability in the FEM estimated failure load most likely stems from the fact that most 
of the biopsies in this study are only 3 mm in diameter.  From there, many of them were cut in 
half, reducing the usable volume down even further.  Trying to extract structural information 
from a sample that small is difficult.  As the biopsy is harvested, a large number of trabecular 
connections are severed.  Each of those connections had a capability to transmit load, but there 
is no way to accurately model those load paths.  The method used in this study to deal with the 
broken connections is the same as that encountered in the literature, which is to leave them 
unconstrained.   That boundary condition is not how the bone behaves in-vivo, but it does 
accurately portray a compression test on the extracted bone.  
According to Harrigan et al., a representative volume of cancellous bone must contain at least 5 
intertrabecular lengths [84], which is 3-5 mm.  The cross sectional area of the vertical iliac 
biopsies in this study ranged from 2.91 to 15.16 mm2 (8.18±3.03 mm2).  Fourteen of the 30 
biopsies in this study had an area less than that of a 3-mm-diameter circle (7.07 mm2).   Even 
more had at least one bounding dimension less than 3 mm.  None of the cross sectional areas 
exceeded the area of a 5-mm-diameter circle.  Published studies which analyze bone biopsies via 
µFE invariably use more than a 3 mm diameter; a 7.5 mm diameter transiliac biopsy is typical 
[49,85,86].  HR-PQCT studies utilizing finite element analysis usually analyze the entire cross 
section of the distal radius [59,87,88].  Studies measuring cancellous bone strength 
experimentally tend to use cylinders around 8mm in diameter [89,90].  
The enormous changes that resulted from using a 4-mm-long region of interest lend credence to 
the fact that the biopsies in this study are too small for reliable finite element analysis.   The 
intra-bone variation at this size scale caused the estimated failure load to more than double for 
some biopsies, and decrease by as much as 12.8% for others.  On average, the BV/TV ratio was 
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altered by 9.76%.  Had the cross sectional area been larger, the biopsies would have behaved 
more like a uniform material, instead of a location-dependent structure.  In order to obtain a 
larger cross section in the future, it would not be out of the ordinary to use a 5-7 mm drill for 
vertical biopsy collection [91].  
Biopsy shape has also been shown to have an effect on strength and modulus.  Keaveny, et al., 
compared the mechanical properties of cancellous bovine bone in the form of cylinders 
(D=5mm, L=10mm) and 5mm cubes [92].  The modulus of the cubes was 36% higher (p<0.01) 
than the cylinders, and their strength was 18% higher (p<0.05).  The biopsies in this research 
were cylinders, half-cylinders, or rectangular prisms.  The range of shapes unquestionably 
increased the amount of variation in the data.   
A small biopsy leaves less material to analyze, and it also increases the likelihood of altering 
connections within the biopsy volume.  Assuming the interior portion of the biopsies survived 
drilling unscathed, the act of handling the removed biopsy still presented an opportunity for 
breaking central trabeculae.  This concern is particularly relevant for poorly connected biopsies 
with low BV/TV.   5.2.2 Biopsy Orientation  
Because of the small biopsy size and the use of previously collected biopsies, there was no 
control over the exact orientation of the biopsy with respect to the pelvic bone.  For the vertical 
biopsies, the entry angle of the trocar dictated the axis of the applied load in the finite element 
analysis.  It is not reasonable to assume that the physician collecting the biopsies used a 
constant angle, especially considering the fact that no single physician collected all of the 
biopsies.  For the transiliac biopsies, the axis of loading was determined by the VOI defined 
during the microCT scan.   The VOI was selected so that it would be in the same plane as the 
vertical biopsies, but there was no way to orient them in the same direction.  Since there was 
already angular uncertainty in the vertical biopsies, the lack of knowledge about transiliac 
orientation was not seen as an impasse.   That being said, the lack of control should not be 
ignored.  Since bone adapts to the loading conditions that it is put under, it is expected that 
biopsy orientation would have a large effect on biopsy strength.  Imagine a plate-like 
architecture such as in biopsy B26.   The biopsy would be strong when the loading is in the plane 
of the plates, and weak when the loading is out of plane.   
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5.2.3 Biopsy Location within the Ilium 
While orientation is important, location also plays a role in biopsy strength.  Imagine if a patient 
had a large number of iliac biopsies performed.  Naturally, there would be some distribution to 
the biopsy strengths.  The question is, just how large is the variability? And, how does the 
variability change as a function of biopsy size?  Cancellous bone is non-homogenous and has 
large features in comparison to the trocar diameter used in this research.  Consequently, the 
deviation between biopsies collected from the same patient could be quite great.  Further 
complicating matters, this study did not take its bone from a consistent portion of the collected 
biopsy.  Many of the biopsies were split into multiple pieces, and no effort was made to always 
select the same portion.  The decision was made because there was no quick way to identify the 
location of each segment with respect to the whole.  In some cases, not all segments were even 
available because prior research rendered them poor candidates for structural analysis.  If each 
experimental group had a large number of patients, the location variability may not be an issue.  
With only 10 biopsies per group, every source of variability must be mitigated.  Even then, there 
is no guarantee of statistical significance when extrapolating bone strength from a small portion 
of bone.   5.2.4 Capture of Biopsy Geometry 
Sub-optimal biopsies may be the cause of some of the variation seen between the groups, but 
there is no changing the biopsies presently in the collection.  In order to make the existing 
biopsies more useful, it may be possible to reduce the erraticism of the downstream operations.  
There is no guarantee that increasing the fidelity of the scanning, meshing, and analysis would 
decrease variability, but it is a goal that should be strived for nonetheless.   
Even with presently available equipment, the scan could be performed at a higher resolution.  A 
pixel size of 6 microns would be achievable with a sample tube diameter of 12.3 mm and an 
image size of 2048x2048 pixels.  (SCANCO rates the µCT40 at a resolution of <8 microns.)  The 
finer resolution would require more computational power from all subsequent operations, but 
could potentially be fruitful.  Using the 12.3 mm sample tube would require that the biopsies be 
embedded in a smaller diameter of acrylic.  Alternatively, they could be machined down in their 
present casting.   
Before going to that extreme, it should be considered that several studies use a scan resolution 
near to or greater than 30 microns.  Harrison et al. have used a 30 micron voxel size [93] and a 
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36 micron size [55] to study ovine trabecular bone.  An experimentally validated model of a rat 
vertebra was created by Naomi and Wroe with 75 micron resolution [94].  A myriad of HR-PQCT 
studies use a voxel size of 80 microns [59,88,95].   
On the other side of the coin, there is evidence to suggest that scan resolution can play a large 
role on the outcome of FEA studies.  Using vertebral trabecular cores (D=8mm, L=25mm) Bevell 
et al. found that increasing the resolution from 20 µm to 40 µm increased the modulus by 42% 
[97].  Perhaps in an effort to avoid this, multiple studies use a resolution below 20 microns.  Liu, 
Cohen, and others have successfully used 8 micron scanning resolutions [49,81].   
Using a higher resolution would make a finer greyscale image of each slice, but the thresholding 
parameters are ultimately responsible for the bone geometry analyzed.  More effort on that 
front could be beneficial to the accuracy of the model.  For example, it may be worthwhile to 
alter the threshold value until the volume of the model matches the experimentally determined 
volume of the biopsy [96].  Others have used a variable threshold based on the maximum 
greyscale value [85].  5.3 Limitations of Study Design 5.3.1 Scope Limited to Cancellous Bone 
On top of the variation due to biopsy orientation and location, there are other fundamental 
factors limiting the applicability of this research.   Chief among them is the fact that the research 
is limited purely to cancellous bone.   Fractures are not seen solely in cancellous bone.  Fractures 
occur across the entire bone cross section; both the cancellous and cortical regions fail.  Any 
study limited to only one type is incomplete.  Boutroy et al. have found that the percent of load 
in the distal radius carried by cancellous bone (64%) is greater in fracture patients than control 
patients [53].  Rats treated with strontium ranelate display a load distribution which is shifted 
8% in favor of cortical bone, whereas untreated rats carry an equal amount of load between 
cortical and cancellous bone [48].   Both of these studies demonstrate that looking at only one 
type of bone is a risky proposition.  At common fracture sites, neither type of bone dominates 
strength.   
That said, the approach is justified on the basis that is does provide some information.  For the 
same amount of cortical bone, weaker cancellous bone will result in lower fracture loads.  Also, 
osteoporotic fractures frequently occur in bones with a large percentage of cancellous bone, 
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notably vertebrae [2].  Cortical bone has a simple geometry, and its strength can be estimated 
by measuring its thickness [98].  Cancellous bone is not so simple.  Trabecular thickness 
influences the strength of cancellous bone, but unlike cortical bone it is also affected by 
connectivity and microarchitecture [49].  So, applying microCT to capture cancellous geometry 
has merit.  However, it must not be forgotten that cancellous bone strength is far from 
predicting fracture loads. It is only one variable correlated to global failure.   5.3.2 Biopsy Location within the Skeletal System     
Accepting the fact that cortical bone is being ignored, there is still a concern regarding the 
location of cancellous bone used in this study.  The ilium is not a frequent fracture site in 
osteoporotic patients, accounting for only 7% of osteoporotic fractures [2].  Atraumatic 
fractures typically occur in the vertebrae, and traumatic fractures commonly befall the hip and 
wrist.  While there is a relationship between bone parameters at the ilium and other locations, it 
still acts as one more layer of complication draped over the already convoluted matter of 
accurately determining the effectiveness of bisphosphonates.  Lamentably, it is not ethical to 
take biopsies from sites prone to fracture in live patients.  The stress concentration from the 
missing bone would increase the already-elevated risk of fracture.  Even if more pertinent 
biopsy locations were feasible, it would be a moot point; the entire reason for this study’s 
existence is to utilize an existing collection of iliac biopsies.  5.3.3 Inaccurate Boundary Conditions 
Even limiting the focus to cancellous bone, the loads applied to the bone in-vivo should be 
applied to the extracted biopsy.  That wasn’t done.  Consistent with common practice 
[59,85,92], the biopsies were analyzed for a state of pure compression.  Such a loading condition 
is rarely, if ever, encountered in the ilium.  Even elsewhere in the body, an evenly distributed 
compressive load is hard to imagine.  For any biological loading, the applied forces will occur at 
the joints and at the points of ligament/tendon attachment.  In the case of traumatic fracture, 
loads may be introduced at any point due to impacts with outside objects.  In all instances, the 
true applied load is a combination of axial, bending, torsional, and shear stresses.  Moreover, 
the joints create Hertzian contact stresses, and the tendons and ligaments introduce point 
loads.  In order to predict bone failure, all of the stresses should be modeled.  With a small 
biopsy, modeling the complex loading condition is not practical.  Since a simplification had to be 
made, compression was chosen as the closest achievable analog to biological loading.   
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Atraumatic fractures, which occur without large external loads, may come closer to a state of 
uniaxial compression than traumatic fractures.  Nonetheless, it would be preferable to model 
and analyze an entire bone.  5.4 Simplifications in the Finite Element Model 5.4.1 Initially Stress-Free 
The fundamental assumptions of a linear elastic model were discussed in the methodology 
section.  In addition to the fundamental assumptions of the model itself, there are a number of 
assumptions typically made in applying it.  For instance, it is assumed that there is no initial 
stress in the material.  Stress in a body with no externally applied loading is called residual 
stress, and can work for or against a structure.   Bone tissue does have residual stresses 
[99,100], but they were not modeled due to the difficulty of determining the proper values over 
the complex microarchitecture.    5.4.2 No Buckling Considerations 
On top of not modeling residual stress, no buckling behavior was considered.  With thin 
trabeculae, buckling failure may precede material failure.  Performing a geometrically nonlinear 
finite element analysis could better model regions with high deformation and capture any 
buckling behavior.   Linear analysis is the dominant type of FEA in medical research due to its 
low computational demands and scaling ability, but there is evidence to suggest that nonlinear 
finite element models are better at predicting failure load when the resolution is 80 microns or 
less [101,102]. On the other hand, research by Macneil and Boyd supports the use of a linear 
model to predict bone strength at a resolution of 82 microns [103].  So, while nonlinear analysis 
has been employed on cancellous bone before [51,55], this research used a linear model for 
convenience.   5.4.3 Homogenous Material Properties 
Just as important as the previous assumptions, the bone material was assumed to be 
homogeneous, isotropic, and linear.  The mechanical properties of trabecular bone are not 
homogeneous.  Rather, they change depending on the location within a trabecula.  In one study, 
the elastic modulus at the center of intertrochanteric trabeculae was 17% higher than that at 
the exterior [104].  The difference was attributed to variations in mineral and collagen 
composition.  In an effort to capture the heterogeneity of bone material, researchers have 
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scaled the material properties of bone based on its radiodensity.  When correlating calculated 
and measured failure load, Macneil et al. found that scaled properties improved the R2 value 
from 0.972 to 0.983 (N=31) [103]. Harrison et al., using heterogeneous material properties, were 
able to accurately determine the apparent modulus of ovine bone [93].  Nevertheless, using 
homogenous properties is commonplace in order to reduce complexity.  Heterogeneous 
properties are relatively easy to apply when the structural mesh is composed of brick elements 
taken directly from the image voxels.  The mesh in this study was based on the STL geometry, so 
it would have been difficult to map the radiodensity to the mesh.   5.4.4 Isotropic Material Properties 
The mechanical properties of bone are also not isotropic [105,106].  This is expected based on 
the anatomy of bone.   It is not formed as one continuous lump; it is laid down in layers.  At the 
smallest length scale the material of bone itself—collagen fibers and hydroxyapatite mineral—
behaves like an anisotropic composite material.   Utilization of anisotropic properties to model 
the mandible has been shown to increase peri-implant stress [107].  There is no doubt that 
modeling the full anisotropic behavior would be best, but it may not be a fruitful endeavor.  In 
diaphyseal cortical bone it is fairly straightforward to apply orientation-dependent properties.  
In cancellous bone, there is no simple way to accomplish the feat.  A coordinate system would 
have to be created for each trabecula, which is not practical to do manually. An algorithm to 
estimate the correct orientation for each element would be necessary.  Additionally, research 
on 29 trabecular whale bone specimens discovered that 92% of the variation in Young’s moduli 
was explained by scaling to a constant tissue-level modulus [108].  When using the modulus of 
the individual samples, the correlation improved to 95%.  The researchers concluded that using 
an “effective isotropic tissue modulus” is an acceptable practice.  Accordingly, the isotropic 
generalization is widely used [55,59,88,93,94].    5.4.5 Linear Material Properties 
Bone material, when considering failure, is not linear [106].   By using a linear material model it 
is impossible to capture the post-yield behavior of the biopsies.  The portion of the stress-strain 
curve for bone after yield is significant, and contributes to the toughness of bone.  On the 
whole-bone level, post-yield behavior may not need to be considered because yield on that 
scale is a form of failure in itself.  However, even for relatively low apparent strains, trabeculae 
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can undergo large deformation.  Ideally, the material in the highly-strained regions would be 
modeled with the full and accurate stress-strain characteristics of bone.   5.4.6 Failure Theory  
No matter how well the material properties are modeled, the final results depend on the 
application of an appropriate failure criterion.  The von Mises criterion is commonly utilized on 
ductile materials when designing to the yield strength of the material.  In order to analyze 
materials prone to brittle fracture, other criteria should be considered.   The maximum principle 
stress criterion is often applied to brittle materials.  The Coulomb-Mohr criterion handles 
materials which—like bone—have different strengths in tension and compression.   (The von 
Mises criterion can be modified to account for the different strengths [51].)  Based on bone’s 
anisotropic nature, the Tsai-Wu failure criterion would be a respectable choice for any 
researcher successful in modeling the true material properties of cancellous bone.  As explained 
in the methodology, this study uses an experimentally-determined strain accumulation failure 
criterion.  It is popular, but it still has room for improvement.    
One notable limitation of the failure criterion in this research is its inability to account for 
fatigue failures.  Osteoporotic bone failure is often a result of cyclic loading, not large static 
forces.  High-trauma fractures do occur by one-time overload, but that opens up a Pandora’s 
Box of modeling issues.  The properties of any material, bone no exception, are dependent on 
the strain rate.  To accurately analyze a high-trauma event would require a dynamic model and 
rate-dependent material properties.  Applying such a model to a small vertical core of cancellous 
bone would not be sensible.   Fatigue failures occur by the generation, growth, and coalescence 
of cracks.  The cracks have openings around 1 micron in width [89], hence they cannot be 
modeled by the SCANCO microCT-40.  It is possible to capture their geometry using nanoCT 
scanners, but the field of view would be severely limited.  Even if a representative volume of 
cancellous bone were scanned at the resolution needed to see microcracks, the computational 
demands of the FE analysis would be astronomical.     
To investigate the effects of cyclic loading and use a tractable number of elements, Guo at al. 
developed an idealized model of trabecular bone [109].  Using Paris’ Law to estimate crack 
growth and element death to remove broken trabeculae, the results for the high-cycle low-
stress analyses were not statistically different (p>0.2) than experimentally-obtained S-N curves 
for bovine trabecular bone.  In the future, his methods could be applied to the non-idealized 
88 
 
geometry of scanned biopsies.  Commercial software, e.g., ANSYS nCode DesignLife, could also 
assist in the fatigue analysis.   5.4.7 Summary 
The limitations mentioned above seem to cast doubt on the finite element analysis, but it is 
undeniably a useful analytical tool.  The calculation of actual stress and strain in bone is far more 
meaningful than any structural index.  Despite all of the assumptions used, the finite element 
analysis in this study positively assesses the quality of microarchitecture, which is a major 
component of cancellous bone strength.  Some of the simplifications in the mathematical model 
have a minimal effect on the outcome, and are only of interest when attempting to explain the 
last bit of variability in test data.  Even if an assumption caused the solution to deviate 
significantly from the true value, all three groups would be exposed to the same method.  So, in 
effect, they would have been treated equally and caparison between them would still be valid.  
Unfortunately, in this study, it was not possible to validate the computational results with 
experimental values.  Doing so would destroy the biopsies, eliminating the possibility of their 
use in all future research.    5.5 Limitations on the Interpretation of Results 
Supposing this research had produced a statistically significant difference between short-term 
and long-term bisphosphonate use, it is crucial to bear in mind that it only would have proven a 
correlation between bisphosphonate duration and bone strength, not causation.  There are a 
multitude of outside variables which could have caused both the longer duration of 
bisphosphonate use and the decreased bone strength.  As a purely hypothetical example, 
suppose there is some set of patient characteristics which causes bisphosphonates to be 
ineffective.  Patients with these characteristics would not show much improvement in bone 
strength.  As a result, their bones would still be relatively weak, even after a long period of using 
bisphosphonates.  Patients without the characteristics would show improvement in BMD, and 
potentially discontinue use of the drug.  After looking at the entire pool of patients, it would be 
tempting to conclude that long-term use decreased patient bone strength.  Whereas, in reality, 
it never did anyone any harm.  It helped one subset of people, and was ineffective on the other.   
Since the groups in this research are age-matched, it is necessarily true that the long-term use 
group started bisphosphonate treatment at a younger age.  Perhaps they became osteoporotic 
at an earlier age due to a genetic predisposition to weak bones.  As a result, they would remain 
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on bisphosphonates for a longer duration, and have weaker bones.  Patients without the 
predisposition would require shorter treatment periods, and have stronger bones.  As in the 
previous example, a confounding variable resulted in a misleading correlation.  Although this 
time the confounder was severity of osteoporosis, and not drug efficacy.   5.6 Applicability of the Method 
The method developed in this research, while replete with simplifications, is still a useful tool for 
the analysis of cancellous bone tissue.   Though it did not show statistical significance, the blame 
cannot be placed exclusively on the finite element modeling.  A large amount of variation is 
inherent in trabecular bone, and it was exacerbated by the small cross-sectional area of the 
biopsies.  The model itself shows convergence of modulus and failure load, indicating that the 
results are mesh independent.  Admittedly, linear tetrahedral elements are universally 
demeaned for having a constant strain, but altering the element type is a simple modification to 
the current method.   A switch to 10-node quadratic tetrahedral elements could be done 
provided that more computational power is made available.  (Using quadratic interpolation 
functions would reduce the number of elements required for convergence, but there is limited 
potential for improvement due to the large number of elements required merely to represent 
the geometry.  The net effect is expected to be an increase in the total degrees of freedom.)  
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6 Conclusion 6.1 Bisphosphonate Treatment Recommendation Based on the Data 
The objective of creating a practicable method for the finite element analysis of iliac crest 
biopsies at the University of Kentucky was achieved.  While this research used only established 
techniques and pre-existing software, they were applied in a unique study of bisphosphonate’s 
effect on bone strength.  The work is novel among other finite element studies in that it 
exploited a pre-existing biopsy bank.  It is distinctive for analyzing predominantly 3-4 mm 
vertical iliac biopsies.  Unlike the majority of cancellous bone FEA studies, which have a pre-
determined brick element size, this effort included a thorough investigation of convergence.  
Another departure from the norm was the use a locally-refined mesh.  Using 8 micron elements 
for an entire biopsy is an inefficient use of resources.  Small elements should only be used to 
capture geometry or steep stress gradients.  The use of ANSYS software was also unique to 
some extent.  ANSYS has been used in many medical studies, but there is a startling dearth of its 
presence in microCT-based bone research.  Standard practice is to either use software 
developed by the microCT manufacturer, or an in-house finite element solver.  Generally, both 
of those avenues have limited capability.  ANSYS opens the floodgates to a torrent of analysis 
options.   
The goal of assessing individual bone strength was partially realized. Biopsy failure loads were 
determined, but they do not directly predict bone strength.  The higher-order objective of 
determining the safety of bisphosphonates, and thereby reducing osteoporotic fractures, was 
arguably a failure.  There is simply too much inherent variation in the biopsies studied to 
observe statistically significant results with groups of 10 biopsies having an average cross 
sectional area of 8.18 mm2.  To elucidate the size problem, imagine what a biopsy would look 
like as the diameter of the core drill approached zero.  At some point around one 
intertrabecular length, the biopsy would be nothing but a disjoined collected of bone fragments.  
Naturally, it is necessary to be far from this state of affairs to extract meaningful information.   
The experimental data were unable to demonstrate a correlation between long-term use of 
bisphosphonates and decreased bone strength.  However, the combination of minimal cross 
sectional area and low sample number resulted in an unsatisfactory statistical power (roughly 
20%).  Thus, no authoritative conclusions can be drawn about the safety of bisphosphonate use.  
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6.2 Future Work 
Experiments focused on making use of the existing biopsy bank must use larger groups to 
decrease the probability of making a type II error.  Extra samples could be obtained by easing 
the inclusion criteria.  Using exclusively low-turnover patients and age-matching the groups 
severely limited the number of eligible biopsies.  Using older biopsies, those removed prior to 
1997, would increase the candidate pool as well.  Moving away from bisphosphonate duration 
studies is another promising route.  Experiments could be focused on fracture status, CKD 
patients, age, BV/TV, turnover, or any number of possible independent variables.   
Aside from including more biopsies, refining the exclusion criteria may increase the usefulness 
of the biopsy bank.  Eliminating certain biopsies a priori could decrease the variability, thereby 
giving higher statistical power for a given sample size.  Reasons for rejection could be: low cross-
sectional area (<7mm2), extreme BV/TV, or exceptionally low connectivity.   
The finite element model itself could be modified, but there is not much evidence to suggest 
that altering the FEM will decrease variability.  Purely on a hunch, the boundary conditions could 
be applied to simulate compressing biopsies in frictionless form-fitting tubes.  The idea is that 
limiting out-of-plane deflection could better model the behavior of bone in-vivo.   (Assuming a 
cylindrical biopsy, the broken trabecular connections at the periphery of the biopsy would not 
be permitted to move in the radial direction.)  In addition to experimenting with boundary 
conditions, biopsy-specific material properties from nanoindentation could easily be used in 
future studies.   Removing any number of the previously-discussed simplifications, such as 
isotropy, homogeneity, or linearity could also be investigated.  Going forward, the results will be 
improved by scanning biopsies prior to histological analysis.  Using a larger diameter drill, up to 
the extent that no undue harm is done to the patient, would also be advantageous to the 
structural analysis.   
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Appendix A: ANSYS ICEM Log File 
ANSYS ICEM CFD STL2DF 14.0 compiled on 10/4/2011 
running on Windows (64 bit version) 
(c) Copyright 1993 - 2011 Ansys Inc. 
Part name... B02110ACR 
From file C:/ICEM/tmpdomain0.uns, imported 1 surfaces, 0 curves, 0 points, 0 materials 
Warning: new surfaces have 703304 triangles -  by default not displaying them 
Current Coordinate system is global 
Please turn on the surfaces in the Entities Tree to display the surfaces. You may want to do this 
only for selective parts. 
Done importing data. 
Global Mesh Size defined 
Volume Meshing Parameters defined 
Writing tetin file temp_tetra.tin ... 
Done saving tetin file. 
Running tetra 
no need to use topo thin 
using user_natural_size = 0.05 for seed rather than 0.25 
1 processes 
about to subdivide 
10,000 tetrahedra 
…abbreviated… 
1,000,000 tetrahedra 
1308979 cells after required subdivision 
slow transition 
1418770 cells after balanced subdivision 
computing diameters 
rounding vertices to curves and surfaces 
updating node connections 
bilateral round to surface 
updating node connections 
splitting edges at surfaces 
25546 edges swapped 
611 edges swapped 
21 edges swapped 
1 edges swapped 
0 edges swapped 
merging mid points 
merging face points 
splitting extra edges 
62119 split edges 
0 split faces 
subdividing based on split edges and faces 
10 edges removed to subdivide the mesh 
problem with edge 75630 75632 
…abbreviated… 
problem with edge 52090 183789 
6 edges removed to subdivide the mesh 
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problem with edge 75630 75632 
…abbreviated… 
problem with edge 52090 183789 
6 edges removed to subdivide the mesh 
problem with edge 75630 75632 
…abbreviated… 
problem with edge 52090 183789 
6 edges removed to subdivide the mesh 
the mesh cannot represent the geometry near -0.866881 -0.594010 -0.626010 
please check for missing prescribed points or curves 
…abbreviated… 
the mesh cannot represent the geometry near 0.430012 3.339527 -1.222550 
please check for missing prescribed points or curves 
updating node connections 
splitting edges at surfaces 
2200 edges swapped 
40 edges swapped 
1 edges swapped 
0 edges swapped 
merging mid points 
merging face points 
splitting extra edges 
13763 split edges 
0 split faces 
subdividing based on split edges and faces 
18 edges removed to subdivide the mesh 
2,000,000 tetrahedra 
problem with edge 260031 371914 
…abbreviated… 
problem with edge 358063 389609 
... and 8 more messages 
16 edges removed to subdivide the mesh 
problem with edge 260031 371914 
…abbreviated… 
problem with edge 364992 381956 
... and 6 more messages 
16 edges removed to subdivide the mesh 
problem with edge 260031 371914 
…abbreviated… 
problem with edge 364992 381956 
... and 6 more messages 
16 edges removed to subdivide the mesh 
the mesh cannot represent the geometry near 0.400184 0.564274 -0.732260 
please check for missing prescribed points or curves 
…abbreviated… 
the mesh cannot represent the geometry near 0.722511 -5.522153 -1.399328 
please check for missing prescribed points or curves 
... and 6 more messages 
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updating node connections 
swapping edges 
running cutter 
computing opaque faces 
adding missing faces 
0 faces added 
63 triangle boxes repaired 
Adding new material point ORFN/-1 outside object at (1.45047 4.71113 0.474794) 
determining material point containment 
Performing flood fill 
2030426 elements marked in ORFN 
family B02110ACR has 275586 internal faces and 40 boundary faces 
but is not marked as internal_wall 
going back 41 steps on path 
Adding new material point CREATED_MATERIAL_2.1 inside object (0.033588 0.802426 
0.194538) 
re-doing flood fill 
material point CREATED_MATERIAL_2.1 can reach material point ORFN/-1 
adding missing face at (x,y,z) = 0.392677, 1.38196, -1.04133 
348497 elements unmarked 
348497 elements remarked in part ORFN 
…abbreviated… 
material point CREATED_MATERIAL_2.1 can reach material point ORFN/-1 
adding missing face at (x,y,z) = 0.656013, -5.99251, -0.415383 
809357 elements unmarked 
0 elements remarked in part ORFN 
809357 elements marked in CREATED_MATERIAL_2 
Adding new material point CREATED_MATERIAL_3.1 inside object (1.29881 -5.95768 -
0.0928376) 
2 elements marked in CREATED_MATERIAL_3 
Adding new material point CREATED_MATERIAL_4.1 inside object (-0.868788 -5.36343 -
0.950233) 
12 elements marked in CREATED_MATERIAL_4 
Adding new material point CREATED_MATERIAL_5.1 inside object (0.212061 0.24967 1.24132) 
5 elements marked in CREATED_MATERIAL_5 
Adding new material point CREATED_MATERIAL_6.1 inside object (-0.253181 3.67857 0.219311) 
2 elements marked in CREATED_MATERIAL_6 
1221069 element(s) are in part ORFN 
809357 element(s) are in part CREATED_MATERIAL_2 
2 element(s) are in part CREATED_MATERIAL_3 
12 element(s) are in part CREATED_MATERIAL_4 
5 element(s) are in part CREATED_MATERIAL_5 
2 element(s) are in part CREATED_MATERIAL_6 
computing bar elements 
unhandled case in fix_spike_node # 401007 
location: -0.554352 -1.11739 -0.755377 
iteration 1: 143 points fixed******************** 
143 spikes fixed 
95 
 
disconnecting orphan cells 
writing out domain file 
Current Coordinate system is global 
New mesh subset "added faces" created 
Smoothing surface mesh... 
Starting smoothing ... 
smooth_elements 0.4 5 smooth TRI_3 float TETRA_4 laplace prism_warp_weight 0.5 nproc 1 
number of processors = 1 
smooth surface elements 
initializing element ratios 
beginning iteration 
iteration 1 completed (Residual 1.000000) 
iteration 2 completed (Residual 0.625877) 
iteration 3 completed (Residual 0.256727) 
iteration 4 completed (Residual 0.131888) 
iteration 5 completed (Residual 0.081069) 
Done smoothing. 
Starting smoothing ... 
smooth_elements 0.4 5 smooth TETRA_4 float PENTA_6 freeze TRI_3 prism_warp_weight 0.5 
nproc 1 
number of processors = 1 
initializing element ratios 
beginning iteration 
 worst TETRA_4 4.82807e-005 
smoothing  8010 TETRA_4's (up to 0.0265147) 
23875 vertices selected 
iteration 1 complete 
 worst TETRA_4 0.00012899 
…abbreviated… 
smoothing  7863 TETRA_4's (up to 0.193558) 
17029 vertices selected 
iteration 5 complete 
worst TETRA_4 0.000259095 
Done smoothing. 
Starting smoothing ... 
smooth_elements 0.4 5 smooth TETRA_4 smooth TRI_3 float PENTA_6 prism_warp_weight 0.5 
nproc 1 
number of processors = 1 
beginning iteration 
 worst TETRA_4 0.000259095 
smoothing  7854 TETRA_4's (up to 0.205407) 
15754 vertices selected 
iteration 1 complete 
 worst TETRA_4 0.0262802 
…abbreviated… 
smoothing  7559 TETRA_4's (up to 0.334458) 
21554 vertices selected 
iteration 5 complete 
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worst TETRA_4 0.161777 
Done smoothing. 
751610 tetrahedra before 
583500 elements 
initializing element ratios 
beginning iteration 
 worst TETRA_4 0.161777 
smoothing  5835 TETRA_4's (up to 0.224473) 
9707 vertices selected 
iteration 1 complete 
 worst TETRA_4 0.161777 
…abbreviated… 
smoothing  5812 TETRA_4's (up to 0.341689) 
3023 vertices selected 
iteration 10 complete 
worst TETRA_4 0.161777 
520245 elements 
beginning iteration 
 worst TETRA_4 0.161777 
smoothing  5202 TETRA_4's (up to 0.233296) 
7038 vertices selected 
iteration 1 complete 
 worst TETRA_4 0.161777 
…abbreviated… 
smoothing  5192 TETRA_4's (up to 0.319001) 
1961 vertices selected 
iteration 10 complete 
worst TETRA_4 0.161777 
519257 tetrahedra after 
Deleted 68190 disconnected vertices 
 
--- Mesh Info --- 
Element types : 
        TETRA_4 : 519257 
        TRI_3 : 246290 
Element parts : 
        B02110ACR : 246290 
        CREATED_MATERIAL_2 : 519253 
        CREATED_MATERIAL_4 : 3 
        CREATED_MATERIAL_5 : 1 
Total elements : 765547 
Total nodes : 153980 
Min : -1.1641 -6.582 -1.82698 
Max : 2.04007 4.678 1.44451 
 
Finished compute mesh 
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Appendix B: ANSYS.in File 
The full B01.in file, with all 32,701 elements, is inconveniently lengthy to include in its entirety.  
Hence, the repetitious sections of the code were removed.  All removed portions have the same 
syntax as the code immediately surrounding them.   
/BATCH 
/NOPR 
/COM, ICEM-ANSYS INTERFACE - Version 13.1 - 
/CONFIG,NPROC,1 
/PREP7 
ET,1,185,,0,,0,,0,0 
/NOLIST 
NBLOCK ,6,SOLID 
(3i8,6e16.9) 
       1       0       0 5.184175491E+00 3.446674824E+00 2.767682374E-01 
       3       0       0 5.219162464E+00 3.393434763E+00 2.518546581E-01 
   …abbreviated… 
   17031       0       0 3.809267521E+00 1.429635644E+00 7.225907445E-01 
   17035       0       0 4.698551178E+00 2.395274162E+00 2.925945222E-01 
N ,R5.3,LOC,     -1 
SHPP,WARN 
EBLOCK ,19,SOLID 
(19i10) !The following block was altered to comma-seperated to fit the page width 
         2,1,0,0,0,0,0,0,8,0,27295,6494,5138,8672,8672,11797,11797,11797,11797 
         2,1,0,0,0,0,0,0,8,0,27296,962,5114,11631,11631,2637,2637,2637,2637 
         …abbreviated… 
         2,1,0,0,0,0,0,0,8,0,59994,55,11945,7273,7273,11283,11283,11283,11283 
         2,1,0,0,0,0,0,0,8,0,59995,1839,12952,819,819,33,33,33,33 
 
-1 
EN ,R5.5,ATTR,     -1 
CMBLOCK,CREATED_MATERIAL_2,NODE,13322 
(8i10) 
         1         3         4         6         7         9        13        14 
        15        17        18        21        22        23        24        25 
     …abbreviated… 
     16996     16997     16998     17001     17002     17003     17004     17005 
     17006     17008     17009     17013     17019     17022     17023     17027 
     17031     17035 
/GOLIST 
NSEL,ALL 
ESEL,ALL 
DOFSEL,ALL 
CMSEL,ALL 
FINISH 
SAVE 
/GOPR 
/SOLU  
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Appendix C: ANSYS APDL Code 
/clear     !start from a clean slate                                   
*dim,biopsies,CHAR,30   !Define the biopsy .in files to be analyzed 
biopsies(1)='B01' 
biopsies(2)='B02' 
biopsies(3)='B03' 
biopsies(4)='B04' 
biopsies(5)='B05' 
biopsies(6)='B06' 
biopsies(7)='B07' 
biopsies(8)='B08' 
biopsies(9)='B09' 
biopsies(10)='B10' 
biopsies(11)='B11' 
biopsies(12)='B12' 
biopsies(13)='B13' 
biopsies(14)='B14' 
biopsies(15)='B15' 
biopsies(16)='B16' 
biopsies(17)='B17' 
biopsies(18)='B18' 
biopsies(19)='B19' 
biopsies(20)='B20' 
biopsies(21)='B21' 
biopsies(22)='B22' 
biopsies(23)='B23' 
biopsies(24)='B24' 
biopsies(25)='B25' 
biopsies(26)='B26' 
biopsies(27)='B27' 
biopsies(28)='B28' 
biopsies(29)='B29' 
biopsies(30)='B30' 
 
*dim,results,array,30,7  !Create the array to store results (rows,columns) 
*DO,I,1,30   !Do loop analyzes each biopsy 
/INPUT,biopsies(I),in  !Opens an .in file instead of a database file 
/prep7     !enter the preprocessing menu; the input code redirects to 
SOLU 
numcmp,elem   !renumber elements starting from 1    
allsel      !Select everything (in case a subset was selected)   
*get,ymin,node,0,mnloc,y !obtain the y axis bounding dimensions 
*get,ymax,node,0,mxloc,y 
BLength=ymax-ymin   !This will simplify later expressions 
nsel,s,loc,y,ymin,ymin+0.05*BLength      !Select nodes in the bottom 5% of the biopsy 
d,all,uy,0    !Define uy=0 for the selected set of nodes 
d,all,ux,0        !Define ux=0 for the selected set of nodes 
d,all,uz,0    !Define uz=0 for the selected set of nodes 
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allsel       
nsel,s,loc,y,ymax-0.05*BLength,ymax   !Select the nodes in the top 5% from the current set  
d,all,uy,-.01*BLength*0.9    !Force the selected nodes to y disp. of 1 percent 
compressive strain 
d,all,ux,0    !Define ux=0 for the selected set of nodes 
d,all,uz,0    !Define uz=0 for the selected set of nodes 
allsel     !Select everything 
mat,1     !Assign mat No.1 to subsequently defined elements 
emodif,all,MAT,1   !Modify all selected elements; set their material to #1 
mp,ex,1,10000    !Define elastic modulus of material 1 to 10000 
mp,nuxy,1,.3    !Define minor Poisson's ratio of material 1 to 0.3 
mp,dens,1,0.001   !Define mass density of material 1 to 0.001 
acel,0,0,0    !Set the acceleration in x,y,and z direction to 0. 
/SOLU     !Enter the solution processor 
eqslv,pcg    !Select the PCG Solver 
SOLVE     !Solve the FE problem 
/POST1 
*get,ElmNum,elem,0,count                !get number of elements in the selected set 
etable,elem_vol,VOLU                      !Create element table with element volumes 
SSUM                                      !sum all of the individual volumes 
*get,totalVol,ssum,0,item,elem_vol         !get the total biopsy volume 
nsel,s,loc,y,(ymax+ymin)/2,ymax  !select the nodes in the top half of the model 
prrs,f     !print the constrained node reaction solution  
FSUM     !Sum the node reaction solution 
*get,totalFy,FSUM,0,ITEM,FY  !Get the total y direction reaction force 
results(I,1)=totalFy   !Store totalFy in the results array 
allsel 
!!!!!!!!!!!!!!!!!!!!!!STRAIN METHOD!!!!!!!!!!!!!!!!!!!!!!! 
etable,strainEQ,EPTO,EQV  !fill element table from equivalent strain 
*dim,strainV,array,ElmNum,2 !create an array to hold strain and volume data 
*vget,strainV(1,1),ELEM,1,ETAB,strainEQ,,,2          !put the strain in the first column 
*vget,strainV(1,2),ELEM,1,ETAB,elem_vol,,,2  !put the volume in the second column 
*MOPER,sort_ord,strainV,SORT,,1   !sort the array by the strain 
currentV=0      !create variable to track volume 
*DO,J,1,ElmNum     !loop thorough the array 
currentV=currentV+strainV(ElmNum+1-J,2)   !Sum volume at each iteration 
 *IF,currentV,GT,0.018*totalVol,THEN !stop when the 2% element is reached 
   strain=strainV(ElmNum+1-J,1) 
 *EXIT 
 *ENDIF 
*ENDDO    
f_load=totalFy*0.007/strain           !Multiply applied load by scale factor   
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!  
 
etable,stressVM,S,EQV  !Create an element table based on von Mises stress 
esort,etab,stressVM,1,1  !Sort the element table by stressVM, in ascending order 
*GET,max_VM,SORT,0,MAX !Save the largest stress as a variable max_VM 
results(I,2)=max_VM  !Put results into the array 
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results(I,3)=totalVol 
results(I,4)=ElmNum 
results(I,5)=blength 
results(I,6)=f_load 
results(I,7)=currentV 
/PREP7 
!nwrite,biopsies(I),txt  !Use this line to write nodes to file (optional) 
*DEL,sort_ord,,NOPR  !Clear Variables before the next analysis 
*DEL,totalVol,,NOPR 
*DEL,strain,,NOPR 
*DEL,ElmNum,,NOPR 
*DEL,maxVM,,NOPR 
*DEL,totalFy,,NOPR 
*DEL,f_load,,NOPR 
*DEL,ymin,,NOPR 
*DEL,ymax,,NOPR 
*DEL,Blength,,NOPR 
*DEL,strainV,,NOPR 
*DEL,J,,NOPR 
*DEL,currentV,,NOPR 
*DEL,max_VM,,NOPR 
/POST1   
ETABLE,ERASE 
FINISH 
PARSAV,all,paramet,parm !Must save the outer DO loop variable  
/clear 
PARRES,new,paramet,parm !Must restore the outer DO loop variable 
*ENDDO 
*cfopen,exportedData,txt !create text file to store output array 
*vwrite    !Write a column header 
('biopsy',9x,'Fy',12x,'maxVM',12x,'Volume',6x,'Elem_Num',8x,'Length',9x,'Fail',10x,'CurVol') 
*vwrite,biopsies(1),results(1,1),results(1,2),results(1,3),results(1,4),results(1,5),results(1,6),re
sults(1,7)    !Write data to the opened text file 
(A8,2X,E13.5,2X,E13.5,2X,E13.5,2X,E13.5,2X,E13.5,2X,E13.5,2X,E13.5) 
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Appendix D: MATLAB Code 
%Cross Sectional Area Finder 
%By Jonathan Ward/Lucas Wilkerson 
%Description: Finds the cross sectional area from the node coordinates of a 
%mesh using the Convex Hull algorithm. Data is exported to an excel file. 
%Variables Used: 
%files     nx1 cell array    string variables of biopsy names 
%num       1                 number of biopsies 
%f         nx6 to nx10       biopsy names in character matrix form 
%data      nx4 double        node numbers and corresponding coordinates 
%x         nx1 double        x coordinates of the nodes 
%z         nx1 double        z coordinates of the nodes 
%K         35x1 double       Convex Hull Index 
%A         1                 cross sectional area 
%s         1                 Either 1 (xlswrite worked) or 0 (failed) 
close all 
clear all 
clc 
files=importdata('biopsy_list_txt.txt'); 
f=char(files); 
for t=1:30 
    data=importdata(char(files(t))); 
    x=data(:,2); 
    z=data(:,4); 
    [K,A] = convhull(x,z); 
    files{t,2}= A; 
    clear x 
    clear z 
    clear data 
    clear A 
end 
s=xlswrite('area_output.xls',files) 
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Appendix E: Biopsy Images 
Figure E-1: Biopsies B01 through B08.  
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Figure E-2: Biopsies B09 through B14. 
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Figure E-3: Biopsies B15 through B20 
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Figure E-4: Biopsies B21 through B26. 
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Figure E-5: Biopsies B27 through B30.  
 
B30 
B29 
B28 B27 
107 
 
Appendix F: Biopsy Patient Information 
Table F-1: Patient Information (Part 1) 
bi
op
sy
 #
 
U
K
 (y
/n
) 
ag
e 
G
ro
up
 
du
ra
tio
n 
yr
s 
bi
sp
h.
 N
am
e 
bi
sp
h.
 D
os
e 
(m
g)
 
do
se
 fr
eq
. 
ov
ar
ie
ct
om
y 
H
R
T 
fa
m
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 h
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to
ry
  
of
 o
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eo
po
ro
si
s 
et
ha
no
l a
bu
se
 
ex
er
ci
se
 
B28 n 67 0          
B04  53 0      1    
B29 y 61 0     0 0  0 0 
B16 y 42 0     1 1  0  
B10 y 72 0     0 1    
B26 n 57 0     0 0    
B25 y 53 0     0 1 0 0  
B23 n 72 0     1 1  0 0 
B11 n 41 0     1 0  0 0 
B14 n 53 0     1     
B22 y 60 1 2 FOSAMAX   0 0 0 0 0 
B24 y 54 1 3 FOSAMAX 70 weekly 1 1 1 1 0 
B21 y 59 1 4 FOSAMAX 70 weekly 0 1 0 0 0 
B30 y 57 1 1.25 ACTONEL 35 weekly  1  0  
B07 y 58 1 2 FOS., ACT. 70 weekly 0 0 1 1 1 
B19 y 63 1 1 BONIVA 150 monthly 0 0  0 0 
B20 y 60 1 4 FOSAMAX 70 weekly 0     
B06 y 59 1 3 FOSAMAX 70 weekly 0 1  0 0 
B13 y 57 1 1.5 FOSAMAX   0 1 0 1 0 
B15 y 55 1 2 FOS., BON., REC.   0 1 0 1 1 
B02 y 54 2 7 FOS., ACT. 35 weekly 0 1 0 0 1 
B09 y 57 2 8 FOS., ACT. 70 weekly 0 0    
B17 y 58 2 7 FOSAMAX 70 weekly 0 1  0 0 
B05 y 54 2 5 FOSAMAX 70 weekly 0 0    
B01 y 64 2 9 FOSAMAX 70 weekly 0 0 0 0 0 
B03 n 61 2 5.5 BONIVA 150 monthly 0 1 0 0  
B08 y 63 2 5 FOSAMAX 70 weekly 0 1 0 1 1 
B12  65 2 13 FOSAMAX   1 1 0 1 1 
B18 y 63 2 12 ACTONEL   0 1 0 0 1 
B27 y 67 2 6 FOSAMAX 70 weekly 0 1 0 1 0 
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Table F-2: Patient Information (Part 2) 
bi
op
sy
 #
 
bm
ds
pi
ne
 (t
-
sc
or
e)
 
bm
dh
ip
 (t
-s
co
re
) 
se
ru
m
 c
al
ci
um
 
se
ru
m
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ho
sp
ha
te
 
se
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m
 c
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e 
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lin
e 
ph
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ph
at
e 
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ne
 s
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fic
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ka
lin
e 
ph
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ph
at
e 
vi
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25
 
vi
td
12
5 
pt
h 
ca
p 
bg
p 
or
 o
st
eo
ca
lin
 
tr
ea
te
d 
w
/ c
al
ci
um
 
B28              
B04   9.7 2.6 0.9   8 32 84  7.6  
B29 -2.6  9.2 3.5 0.7 68    55  17.5 0 
B16 -1.4 -2.1 8.7 3.6 0.9 68  25 67 47  6.5 1 
B10   9.3 3.5 0.6 47  18 42 25  9.4 1 
B26   9.6   110   35.3 30   1 
B25 -2  9.1 0.7 3.9  28.9  32    1 
B23   9 2.9 2 45  24  56   0 
B11   9.6 4.7 0.7 37 25 64 53    0 
B14   8.9 4  138  8  5    
B22   9.6 3 0.7 66  53 33 49  4.0 1 
B24 -2.42  9.4   46       1 
B21 -1 -0.9 9.2 3.9 0.9 87    26   1 
B30 -2.9 -1.7 9.1 4.3 0.9 42 22.6 65 63 17  1.7 1 
B07 -2.2   3.9 0.8 58  42   34.3 2.6 0 
B19 -3 -1.2     10 39   19 19 0 
B20 -3.5 -0.9  4.9 1  9 29   13 13 0 
B06   9.3 4.3 0.74     22   0 
B13 -2.9 -2.3     15.7 41   19 15 1 
B15  -1.88   0.65  11.9 36   21 15 1 
B02 -2.8 -2.11 9.2 2.8 0.8  10.2 102 25 9  13.7 1 
B09 -2.5 -2.5  4.9   10.4 28   22 19 0 
B17 -2.2 -2.5 9.4   78  42  47  15 1 
B05   10.1 3.7 0.74  21.7 45  33 8 22 0 
B01 -3.1 -2.6 9.4 3.6 0.77 62 11.1 34 58  28  0 
B03 -0.6  9.1 3.7 1.04   51     1 
B08 -1.19 -2.6 9.6 3.6 0.77   52 104  25 14 1 
B12   9.7 3.7 0.95 37 6.8 45  27   1 
B18 -1.47 -2.01 9.2 4.1 0.77 56 8.3 106  34  9 1 
B27 -0.4 -2.9 8.9 3.2 0.87  5.2 57  29   1 
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Table F-3: Patient Information (Part 3) 
bi
op
sy
 #
 
bo
ne
 p
ai
n 
fr
ac
tu
re
 
m
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t. 
fr
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s 
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/n
) 
fr
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w
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gh
t 
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B28  1 y  0    
B04  1       
B29 1 0   1    
B16 0 1 y  1  136  
B10 0 1   1    
B26  1   0    
B25 0 0   0 63 96  
B23 0 0   1 61 154 barrett's esoph. 
B11 0 0   1    
B14         
B22 0 0   0    
B24 0 0   0 65 136  
B21 0 1 y low 0 65 169  
B30 0 1   0    
B07 0 0   0   MS 
B19  1  high 1  191 hyperlipidemia 
B20 1    1  130  
B06 1 1 y  1  186 CKD III 
B13 0 1   1 59 123 OI, RA 
B15 1 1 y  1  137 Breast CA 
B02 0 0   1 60 125 hypothyroid 
B09 0 0   1  139   
B17 0 1  high 1 63 160  
B05 0 0   1  129 OI 
B01 0 1 y  1 62 111  
B03 1 1 y lo./hi. 1 63 217 arthritis 
B08 0 0   1 64 106   
B12 0 0   1 62 167   
B18 0 1   1 62 165 OA 
B27 0 1  high 1 63 118  
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Appendix G: Raw Data 
Table G-1: Coarse Mesh Output Data 
biopsy Fy [N] 
σmax 
[MPa] 
BV 
[mm3] Elem # 
Length 
[mm] Fult [N] 
Area 
[mm2] 
B01 6.00 720 5.08 32701 9.66 4.72 4.71 
B02 11.33 425 5.74 38375 7.83 8.23 2.91 
B03 55.32 870 16.59 67081 9.00 28.26 6.93 
B04 9.57 622 12.27 25258 12.84 7.20 8.28 
B05 14.85 659 13.06 34873 12.89 11.03 7.07 
B06 17.83 606 15.82 29106 12.36 12.88 6.19 
B07 40.22 1001 15.23 77787 7.51 24.13 13.26 
B08 11.46 777 9.30 43647 11.26 8.16 6.81 
B09 7.99 917 7.56 48887 9.62 6.81 5.63 
B10 6.36 471 11.31 39221 13.09 6.16 9.47 
B11 53.29 1249 14.38 133190 6.94 30.89 14.44 
B12 3.86 516 9.35 28723 9.95 4.80 8.01 
B13 24.56 899 14.67 47907 9.37 15.54 6.76 
B14 126.54 1384 45.74 109320 11.42 65.85 15.16 
B15 3.89 404 5.51 46740 7.23 4.16 6.37 
B16 17.60 1286 10.16 43095 9.86 11.03 8.17 
B17 16.52 1004 6.55 67154 7.49 10.25 5.92 
B18 13.43 426 7.61 33474 9.12 9.48 6.56 
B19 0.15 85 1.70 27451 4.56 0.53 6.87 
B20 32.61 829 23.11 31439 16.21 18.38 7.44 
B21 255.10 746 41.33 92402 9.73 110.53 8.98 
B22 20.62 680 15.03 45690 12.09 13.61 9.69 
B23 27.42 701 11.36 102080 6.72 18.49 12.19 
B24 146.59 1110 48.88 66551 15.46 66.63 9.38 
B25 8.20 1026 12.54 61843 10.97 7.51 11.28 
B26 136.79 928 30.72 68432 12.50 62.20 12.74 
B27 4.95 1964 7.57 39351 13.87 4.25 6.61 
B28 1.87 238 6.50 42974 7.67 3.02 3.86 
B29 15.22 694 5.89 69099 6.16 9.99 8.49 
B30 5.06 413 9.09 32076 12.12 4.94 5.33 
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Table G-2: Coarse Mesh Derived Data 
biopsy TV [mm3] BV/TV 
Py 
[MPa] SAR 
E 
[MPa] 
Eeff 
[MPa] 
Pfail 
[MPa] 
B01 45.53 0.112 1.27 566.0 127.2 1141.1 1.00 
B02 22.78 0.252 3.90 109.0 389.7 1546.0 2.83 
B03 62.37 0.266 7.98 109.0 798.3 3000.4 4.08 
B04 106.30 0.115 1.16 538.4 115.5 1001.1 0.87 
B05 91.17 0.143 2.10 313.8 210.0 1466.1 1.56 
B06 76.52 0.207 2.88 210.6 287.9 1392.9 2.08 
B07 99.60 0.153 3.03 330.1 303.2 1982.6 1.82 
B08 76.70 0.121 1.68 461.7 168.3 1388.2 1.20 
B09 54.15 0.140 1.42 646.1 142.0 1017.1 1.21 
B10 123.95 0.091 0.67 701.1 67.1 735.9 0.65 
B11 100.24 0.143 3.69 338.5 369.0 2571.9 2.14 
B12 79.66 0.117 0.48 1071.0 48.2 410.5 0.60 
B13 63.31 0.232 3.63 247.4 363.5 1569.0 2.30 
B14 173.21 0.264 8.35 165.8 834.6 3160.7 4.34 
B15 46.05 0.120 0.61 660.8 61.1 511.3 0.65 
B16 80.57 0.126 2.15 597.3 215.4 1708.8 1.35 
B17 44.35 0.148 2.79 360.0 278.9 1889.3 1.73 
B18 59.80 0.127 2.05 208.2 204.8 1609.3 1.45 
B19 31.34 0.054 0.02 3848.8 2.2 40.7 0.08 
B20 120.67 0.192 4.38 189.2 438.1 2287.2 2.47 
B21 87.40 0.473 28.40 26.3 2839.8 6005.6 12.30 
B22 117.12 0.128 2.13 319.3 212.9 1659.1 1.41 
B23 81.94 0.139 2.25 311.7 224.9 1621.9 1.52 
B24 145.00 0.337 15.63 71.0 1563.0 4636.1 7.10 
B25 123.76 0.101 0.73 1412.7 72.7 717.2 0.67 
B26 159.21 0.193 10.74 86.4 1074.1 5567.4 4.88 
B27 91.65 0.083 0.75 2624.3 74.8 906.0 0.64 
B28 29.62 0.219 0.48 492.0 48.5 220.8 0.78 
B29 52.33 0.113 1.79 387.5 179.1 1592.1 1.18 
B30 64.62 0.141 0.95 435.5 94.8 673.7 0.93 
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Table G-3: Fine Mesh Output Data 
biopsy Fy [N] 
σmax 
[MPa] 
BV 
[mm3] Elem # 
Length 
[mm] 
Fult 
[N] 
Area 
[mm2] 
B01 5.27 937 5.58 301320 9.66 4.57 4.71 
B02 8.58 466 5.97 239610 7.83 7.10 2.91 
B03 46.77 1295 17.09 647250 9.00 25.86 6.93 
B04 6.65 1101 14.30 745960 12.84 6.59 8.28 
B05 11.38 1147 14.30 609380 12.89 9.42 7.07 
B06 14.08 610 16.93 461860 12.36 11.43 6.19 
B07 36.24 1177 16.18 699340 7.51 23.43 13.26 
B08 9.49 2218 10.18 519250 11.26 7.63 6.81 
B09 5.54 869 8.09 404590 9.62 5.71 5.63 
B10 5.01 1533 12.90 590000 13.09 5.76 9.47 
B11 49.86 890 15.48 899670 6.94 30.44 14.44 
B12 2.64 1048 10.53 418740 9.95 4.11 8.01 
B13 21.48 787 15.25 447290 9.37 14.68 6.76 
B14 106.68 1697 47.15 941290 11.43 59.95 15.16 
B15 3.26 414 6.09 367380 7.23 4.03 6.37 
B16 14.95 1928 11.35 562320 9.86 10.68 8.17 
B17 14.72 2072 7.00 444060 7.49 9.87 5.92 
B18 11.15 621 8.23 346970 9.12 8.84 6.56 
B19 0.12 104 1.88 130930 4.56 0.48 6.87 
B20 23.63 1974 24.77 723250 16.21 15.86 7.44 
B21 219.65 2523 41.41 1140200 9.73 99.50 8.98 
B22 17.10 1228 16.49 720860 12.09 13.00 9.69 
B23 23.63 868 12.02 610270 6.72 17.42 12.19 
B24 120.42 1586 49.77 860050 15.46 58.41 9.38 
B25 6.94 857 13.99 710670 10.97 7.32 11.28 
B26 129.05 1052 31.93 704390 12.50 60.44 12.74 
B27 4.54 1954 9.07 593940 13.87 4.55 6.61 
B28 1.38 264 6.93 284470 7.67 2.68 3.86 
B29 15.17 1133 6.43 421800 6.16 10.36 8.49 
B30 4.05 1121 10.03 431100 12.12 4.65 5.33 
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Table G-4: Fine Mesh Derived Data 
biopsy TV [mm3] BV/TV 
Py 
[MPa] SAR 
E 
[MPa] 
Eeff 
[MPa] 
Pfail 
[MPa] 
B01 45.53 0.123 1.12 838.9 111.8 911.3 0.97 
B02 22.78 0.262 2.95 158.1 294.9 1125.8 2.44 
B03 62.37 0.274 6.75 191.8 675.0 2463.4 3.73 
B04 106.30 0.135 0.80 1371.2 80.3 596.7 0.80 
B05 91.17 0.157 1.61 713.0 160.8 1025.1 1.33 
B06 76.52 0.221 2.27 268.2 227.5 1028.2 1.85 
B07 99.61 0.162 2.73 430.8 273.2 1681.8 1.77 
B08 76.70 0.133 1.39 1592.1 139.3 1050.0 1.12 
B09 54.15 0.149 0.98 882.6 98.5 659.5 1.01 
B10 123.95 0.104 0.53 2900.3 52.9 507.8 0.61 
B11 100.22 0.154 3.45 257.9 345.3 2236.2 2.11 
B12 79.66 0.132 0.33 3173.2 33.0 249.9 0.51 
B13 63.30 0.241 3.18 247.5 317.9 1319.7 2.17 
B14 173.23 0.272 7.04 241.1 703.6 2584.9 3.95 
B15 46.05 0.132 0.51 808.1 51.2 386.8 0.63 
B16 80.57 0.141 1.83 1053.8 183.0 1298.9 1.31 
B17 44.35 0.158 2.49 833.2 248.6 1574.9 1.67 
B18 59.80 0.138 1.70 365.1 170.1 1236.4 1.35 
B19 31.34 0.060 0.02 6148.7 1.7 28.1 0.07 
B20 120.67 0.205 3.17 622.1 317.3 1546.1 2.13 
B21 87.41 0.474 24.45 103.2 2445.2 5161.0 11.08 
B22 117.12 0.141 1.76 695.8 176.5 1253.8 1.34 
B23 81.94 0.147 1.94 447.8 193.8 1321.3 1.43 
B24 145.00 0.343 12.84 123.5 1283.9 3740.6 6.23 
B25 123.76 0.113 0.62 1392.4 61.5 544.1 0.65 
B26 159.22 0.201 10.13 103.8 1013.3 5053.4 4.75 
B27 91.65 0.099 0.69 2846.7 68.6 693.6 0.69 
B28 29.62 0.234 0.36 738.4 35.8 152.9 0.69 
B29 52.33 0.123 1.79 634.7 178.6 1453.2 1.22 
B30 64.62 0.155 0.76 1475.1 76.0 490.0 0.87 
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Table G-5: Fixed-Length Output Data 
biopsy Fy [N] 
σmax 
[MPa] 
BV 
[mm3] Elem # 
Length 
[mm] Fult [N] 
Area 
[mm2] 
B01 7.49 393 2.27 122990 4.115 5.31 4.71 
B02 8.94 436 2.87 120420 4.124 7.10 2.91 
B03 52.48 929 7.49 275050 4.188 27.77 6.93 
B04 6.90 779 3.81 232990 4.143 6.37 8.28 
B05 19.11 714 4.33 168960 4.127 11.80 7.07 
B06 16.67 497 5.07 148510 4.199 11.78 6.19 
B07 35.59 1246 6.98 338210 4.136 21.38 13.26 
B08 12.13 1329 3.18 160630 4.130 8.50 6.81 
B09 4.83 385 3.57 175830 4.115 5.32 5.63 
B10 8.40 365 4.24 182200 4.141 7.42 9.47 
B11 56.64 581 8.58 498010 4.120 32.49 14.44 
B12 7.68 2280 4.61 166130 4.212 7.64 8.01 
B13 62.16 729 7.72 191180 4.182 30.24 6.76 
B14 120.25 922 16.23 462960 4.167 65.86 15.16 
B15 4.13 334 3.07 209240 4.120 4.36 6.37 
B16 16.35 2225 4.48 232940 4.159 10.61 8.17 
B17 13.24 1366 3.36 201060 4.114 8.60 5.92 
B18 13.86 399 3.59 142030 4.147 9.63 6.56 
B19 0.11 101 1.61 113310 4.118 0.46 6.87 
B20 36.28 805 7.12 179720 4.198 20.13 7.44 
B21 218.34 1980 16.07 464620 4.203 103.33 8.98 
B22 26.94 437 5.80 230280 4.112 16.77 9.69 
B23 26.08 4948 6.65 329370 4.148 18.17 12.19 
B24 180.69 1370 14.82 328700 4.211 92.50 9.38 
B25 15.68 859 5.66 279430 4.139 11.64 11.28 
B26 152.17 889 9.82 206020 4.198 71.39 12.74 
B27 7.03 1137 2.54 175650 4.096 5.49 6.61 
B28 1.66 319 2.83 121990 4.134 2.58 3.86 
B29 14.08 900 3.80 258820 4.104 9.39 8.49 
B30 9.35 1699 3.83 167040 4.127 7.79 5.33 
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Table G-6: Fixed-Length Derived Data 
biopsy TV [mm3] BV/TV 
Py 
[MPa] SAR 
E 
[MPa] 
Eeff 
[MPa] 
Pfail 
[MPa] 
B01 19.39 0.117 1.59 247.5 159.0 1355.3 1.13 
B02 12.00 0.239 3.08 141.9 307.5 1285.2 2.44 
B03 29.02 0.258 7.57 122.7 757.3 2934.0 4.01 
B04 34.30 0.111 0.83 934.7 83.4 750.8 0.77 
B05 29.19 0.148 2.70 264.2 270.1 1819.3 1.67 
B06 25.99 0.195 2.69 184.4 269.2 1379.3 1.90 
B07 54.86 0.127 2.68 464.2 268.3 2109.4 1.61 
B08 28.13 0.113 1.78 746.1 178.1 1573.8 1.25 
B09 23.16 0.154 0.86 448.0 85.9 557.0 0.94 
B10 39.21 0.108 0.89 411.7 88.8 820.4 0.78 
B11 59.48 0.144 3.92 148.2 392.3 2719.8 2.25 
B12 33.72 0.137 0.96 2376.3 96.0 702.2 0.95 
B13 28.26 0.273 9.20 79.3 920.0 3366.6 4.48 
B14 63.17 0.257 7.93 116.3 793.1 3087.2 4.34 
B15 26.24 0.117 0.65 515.0 64.9 554.1 0.69 
B16 33.98 0.132 2.00 1112.4 200.0 1517.4 1.30 
B17 24.36 0.138 2.24 611.1 223.6 1620.3 1.45 
B18 27.19 0.132 2.11 188.8 211.4 1599.6 1.47 
B19 28.30 0.057 0.02 6208.4 1.6 28.5 0.07 
B20 31.25 0.228 4.87 165.2 487.3 2137.5 2.70 
B21 37.76 0.426 24.31 81.5 2430.6 5711.5 11.50 
B22 39.83 0.146 2.78 157.2 278.1 1909.3 1.73 
B23 50.58 0.131 2.14 2313.9 213.8 1627.6 1.49 
B24 39.50 0.375 19.27 71.1 1926.5 5132.9 9.86 
B25 46.70 0.121 1.39 618.4 139.0 1146.9 1.03 
B26 53.47 0.184 11.95 74.4 1194.8 6507.6 5.61 
B27 27.07 0.094 1.06 1068.8 106.3 1134.2 0.83 
B28 15.97 0.177 0.43 744.2 42.9 241.6 0.67 
B29 34.86 0.109 1.66 543.3 165.7 1521.3 1.11 
B30 22.01 0.174 1.75 968.2 175.4 1009.2 1.46 
  
116 
 
References 
1. "Debunking the Myths." Home. National Osteoporosis Foundation, n.d. Web. 22 
Oct. 2012. <http://www.nof.org/articles/4>. 
2. Burge, Russel, Bess Dawson-Hughes, Daniel H. Solomon, John B. Wong, Alison King, 
and Anna Tosteson. "Incidence and Economic Burden of Osteoporosis-Related 
Fractures in the United States, 2005-2025." Journal of Bone and Mineral 
Research 22.3 (2007): 465-75. Print. 
3. Odden, Michelle C., Pamela G. Coxson, Andrew Moran, James M. Lightwood, Lee 
Goldman, and Kirsten Bibbins-Domingo. "The Impact of the Aging Population on 
Coronary Heart Disease in the United States." The American Journal of 
Medicine124.9 (2011): 827-33.e5. Print. 
4. Benton, Melissa, and Andrea White. "Osteoporosis: Recommendations for 
Resistance Exercise and Supplementation With Calcium and Vitamin D to Promote 
Bone Health."Journal of Community Health Nursing 23.4 (2006): 201-11. Print 
5. Smith, R. "Exercise and Osteoporosis." Bmj 290.6476 (1985): 1163-164. Print. 
6. O'Brien, M. "Osteoporosis and Exercise." British Journal of Sports Medicine 30.3 
(1996): 191. Print. 
7. Mayo Clinic Staff. "Osteoporosis Treatment: Medications Can Help." Mayo Clinic. 
Mayo Foundation for Medical Education and Research, 23 Aug. 2011. Web. 22 Oct. 
2012. <http://www.mayoclinic.com/health/osteoporosis-treatment/WO00127>. 
8. American Dental Association Counsel on Scientific Affairs. "Dental Management of 
Patients Receiving Oral Bisphosphonate Therapy." Journal of the American Dental 
Assocation 137.8 (2006): 1144-150. JADA. American Dental Assocation, 2006. Web. 
19 Aug. 2012. <http://jada.ada.org/cgi/content/full/137/8/1144>. 
9. Cagnetta, V., and V. Patella. "The Role of the Immune System in the 
Physiopathology of Osteoporosis." Clinical Cases in Mineral and Bone 
Metabolism 9(2) (2012): 85-88. Clinical Cases in Mineral and Bone Metabolism, 
May-June 2012. Web. 23 Oct. 2012. 
<http://www.ncbi.nlm.nih.gov/pmc/issues/215517/>. 
10. Rivadeneira, Fernando. "Hunting Osteoporosis Susceptibility Genes: Bigger Is Better 
but Diverse Is Also Welcome." Endocrine, 22 Sept. 2012. Web. 23 Oct. 2012. 
http://www.springerlink.com/content/591134722m17uk00/fulltext.pdf 
11. Merom, D., and V. Pye. "Prevalence and Correlates of Participation in Fall 
Prevention Exercise/physical Activity by Older Adults." Preventive Medicine (2012): 
[Epub ahead of print] Web. 23 Oct. 2012. 
<http://www.sciencedirect.com/science/article/pii/S0091743512004756>. 
12. Ott, S. M. "Long-Term Safety of Bisphosphonates." Journal of Clinical Endocrinology 
& Metabolism 90.3 (2004): 1897-899. Print. 
13. Day, J. "Bisphosphonate Treatment Affects Trabecular Bone Apparent Modulus 
through Micro-architecture Rather than Matrix Properties." Journal of Orthopaedic 
Research 22.3 (2004): 465-71. Print. 
14. Tam, Cherk S., and William Anderson. "Tetracycline Labeling of Bone in 
Vivo." Calcified Tissue International 30.1 (1980): 121-25. Print. 
15. Malluche, Hartmut H., Hanna Mawad, and Marie-Claude Monier-Faugere. "Bone 
Biopsy in Patients with Osteoporosis." Current Osteoporosis Reports 5.4 (2007): 146-
52. Print. 
16. Timoshenko, Stephan P. History of Strength of Materials. New York: McGraw-Hill, 
1953. Print. 
117 
 
17. Johnell, O. "Advances in Osteoporosis : Better Identification of Risk Factors Can 
Reduce Morbidity and Mortality." Journal of Internal Medicine (1996): 239+. Print. 
18. Johnell, O., J. A. Kanis, A. Oden, I. Sernbo, I. Redlund-Johnell, C. Petterson, C. De 
Laet, and B. Jonsson. "Mortality after Osteoporotic Fractures." Osteoporosis 
International15.1 (2004): 38-42. Print. 
19. Bolland, M. J., and A. Grey. "The Effect of Treatments for Osteoporosis on 
Mortality."Osteoporos Int (2012) [published online ahead of print] 
Http://www.springerlink.com/content/9260nr0445032048/fulltext.pdf. 18 Oct. 
2012. Web. 24 Oct. 2012. 
20. Compston, Juliet. "Osteoporosis: Social and Economic Impact." Radiologic Clinics of 
North America 48.3 (2010): 477-82. Print. 
21. Black, Dennis M., Steven R. Cummings, Harry K. Genant, Michael C. Nevitt, Lisa 
Palermo, and Warren Browner. "Axial and Appendicular Bone Density Predict 
Fractures in Older Women." Journal of Bone and Mineral Research 7.6 (1992): 633-
38. Print. 
22. Bone, Henry G., Arthur C. Santora, Arghya Chattopadhyay, and Uri Liberman. "Are 
We Treating Women With Postmenopausal Osteoporosis for Their Low BMD or High 
Fracture Risk?" Journal of Bone and Mineral Research 20.11 (2005): 2064-065. Print. 
23. Geusens, Piet, Tineke Van Geel, Kirsten Huntjens, Sven Van Helden, Sandrine Bours, 
and Joop Van Den Bergh. "Clinical Fractures beyond Low BMD." International 
Journal of Clinical Rheumatology 6.4 (2011): 411-21. Print. 
24. Heymsfield, Steven. Human Body Composition. Champaign, IL: Human Kinetics, 
2005. Print. 
25. Whiting, William Charles., and Stuart Rugg. Dynatomy: Dynamic Human Anatomy. 
Vol. 10. Champaign, IL: Human Kinetics, 2006. Print. 
26. Hannah, K.M., C.D.L. Thomas, J.G. Clement, F. De Carlo, and A.G. Peele. "Bimodal 
Distribution of Osteocyte Lacunar Size in the Human Femoral Cortex as Revealed by 
Micro-CT." Bone 47.5 (2010): 866-71. Print. 
27. Pazzaglia, Ugo E., and Terenzio Congiu. "The Cast Imaging of the Osteon Lacunar-
canalicular System and the Implications with Functional Models of Intracanalicular 
Flow."Journal of Anatomy (2012): [Epub ahead of print] Web. 3 Nov. 2012. 
<http://onlinelibrary.wiley.com/doi/10.1111/joa.12004/abstract>. 
28. Teraoka, K., A. Ito, K. Maekawa, K. Onuma, T. Tateishi, and S. Tsutsumi. "Mechanical 
Properties of Hydroxyapatite and OH-carbonated Hydroxyapatite Single 
Crystals."Journal of Dental Research 77.7 (1998): 1560-568. Print. 
29. Rho, Jae Young, Richard B. Ashman, and Charles H. Turner. "Young's Modulus of 
Trabecular and Cortical Bone Material: Ultrasonic and Microtensile 
Measurements."Journal of Biomechanics 26.2 (1993): 111-19. Print. 
30. Krum, S. A., and M. Brown. "Unraveling Estrogen Action in Osteoporosis." Cell 
Cycle 7.10 (2008): 1348-352. Print. 
31. Mariotti, Angelo. "Bisphosphonates and Osteonecrosis of the Jaws." Journal of 
Dental Education 72.8 (2008): 919-29. Print. 
32. Neviaser, Andrew S., Joseph M. Lane, Brett A. Lenart, Folorunsho Edobor-Osula, and 
Dean G. Lorich. "Low-Energy Femoral Shaft Fractures Associated With Alendronate 
Use."Journal of Orthopaedic Trauma 22.5 (2008): 346-50. Print. 
33. Van Der Meulen, M. C., and A. L. Boskey. "Atypical Subtrochanteric Femoral Shaft 
Fractures: Role for Mechanics and Bone Quality." Arthritis Research Therapy 14.4 
118 
 
(2012): 220. PubMed.gov. NIH, 20 Aug. 2012. Web. 4 Sept. 2012. 
<http://www.ncbi.nlm.nih.gov/pubmed/22958475>. 
34. Gupta, K. K., and J. L. Meek. "A Brief History of the Beginning of The Finite Element 
Method." International Journal for Numerical Methods in Engineering 39.22 (1996): 
3761-774. Print. 
35. Mackie, R. I. "Object Oriented Programming of the Finite Element 
Method." International Journal for Numerical Methods in Engineering 35.2 (1992): 
425-36. Print. 
36. Babuška, Ivo, and Theofanis Strouboulis. The Finite Element Method and Its 
Reliability. Oxford England: Clarendon, 2001. Print. 
37. Bilezikian, J. "Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal 
Osteoporosis." The American Journal of Medicine 122.2 (2009): S14-21. Print. 
38. Pazianas, Michael, Solomon Epstein, and Mone Zaidi. "Evaluating the Antifracture 
Efficacy of Bisphosphonates." Reviews on Recent Clinical Trials 4.2 (2009): 122-30. 
Print. 
39. Green, J. O., T. Diab, M. R. Allen, B. Vidakovic, D. B. Burr, and R. E. Guldberg. "Three 
Years of Alendronate Treatment Does Not Continue to Decrease Microstructural 
Stresses and Strains Associated with Trabecular Microdamage Initiation beyond Those 
at 1 Year." Osteoporosis International 23.9 (2012): 2313-20. Print. 
40. Allen, M. R., and D. B. Burr. "Changes in Vertebral Strength-density and Energy 
Absorption-density Relationships following Bisphosphonate Treatment in Beagle 
Dogs."Osteoporosis International 19.1 (2008): 95-99. Print. 
41. Allen, Matthew R., and David B. Burr. "Bisphosphonate Effects on Bone Turnover, 
Microdamage, and Mechanical Properties: What We Think We Know and What We 
Know That We Don't Know." Bone 49.1 (2011): 56-65. Print. 
42. FDA. Possible Increased Risk of Thigh Bone Fracture with Bisphosphonates. U.S. Food 
and Drug Administration. N.p., 13 Oct. 2010. Web. 20 Aug. 2012. 
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm
>. 
43. Watts, N. B., and D. L. Diab. "Long-Term Use of Bisphosphonates in 
Osteoporosis." Journal of Clinical Endocrinology & Metabolism 95.4 (2010): 1555-565. 
Print 
44. Hampson, Geeta, and Ignac Fogelman. "Clinical Role of Bisphosphonate 
Therapy."International Journal of Women’s Health 4 (2012): 455-69. NCBI. NIH, 3 Sept. 
2012. Web. 15 Mar. 2012. 
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469225/>. 
45. Komatsubara, Satoshi, Satoshi Mori, Tasuku Mashiba, Jilliang Li, Kiichi Nonaka, Yoshio 
Kaji, Tomoyuki Akiyama, Kensaku Miyamoto, Yongping Cao, Jun Kawanishi, and 
Hiromichi Norimatsu. "Suppressed Bone Turnover by Long-Term Bisphosphonate 
Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in 
Cortical Bone of Dog Rib." Journal of Bone and Mineral Research 19.6 (2004): 999-
1005. Print. 
46. Forwood, M. "Bisphosphonates Are Associated with Microdamage Accumulation at 
Clinically Relevant Skeletal Sites in Beagles." Bone 27.4 (2000): 27. Print. 
47. Chapurlat, Roland D., Monique Arlot, Brigitte Burt-Pichat, Pascale Chavassieux, Jean 
Paul Roux, Nathalie Portero-Muzy, and Pierre D. Delmas. "Microcrack Frequency and 
119 
 
Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term 
Bisphosphonates: A Bone Biopsy Study." Journal of Bone and Mineral Research22.10 
(2007): 1502-509. Print. 
48. Boyd, Steven K., Eva Szabo, and Patrick Ammann. "Increased Bone Strength Is 
Associated with Improved Bone Microarchitecture in Intact Female Rats Treated with 
Strontium Ranelate: A Finite Element Analysis Study."Bone 48.5 (2011): 1109-116. 
Print. 
49. Liu, X. Sherry, Adi Cohen, Elizabeth Shane, Emily Stein, Halley Rogers, Shannon L. 
Kokolus, Perry T. Yin, Donald J. McMahon, Joan M. Lappe, Robert R. Recker, and X. 
Edward Guo. "Individual Trabeculae Segmentation (ITS)-based Morphological Analysis 
of High-resolution Peripheral Quantitative Computed Tomography Images Detects 
Abnormal Trabecular Plate and Rod Microarchitecture in Premenopausal Women with 
Idiopathic Osteoporosis." Journal of Bone and Mineral Research 25.7 (2010): 1496-505. 
Print. 
50. Hansen, Stinus, Kim Brixen, and Claus H. Gravholt. "Compromised Trabecular 
Microarchitecture and Lower Finite Element Estimates of Radius and Tibia Bone 
Strength in Adults with Turner Syndrome: A Cross-sectional Study Using High-
resolution-pQCT." Journal of Bone and Mineral Research 27.8 (2012): 1794-803. Print. 
51. Amin S, S., D. L. Kopperdhal, L. J. Melton, 3rd, S. J. Achenbach, T. M. Therneau, B. L. 
Riggs, T. M. Keaveny, and S. Khosla. "Association of Hip Strength Estimates by Finite-
element Analysis with Fractures in Women and Men." Journal of Bone and Mineral 
Research 26.7 (2011): 1593-600. Print. 
52. Brosses, Emily, E. Jolivet, C. Travert, D. Mitton, and W. Skalli. "Prediction of the 
Vertebral Strength Using a Finite Element Model Derived from Low-dose Biplanar 
Imaging: Benefits of Subject-specific Material Properties." Spine 37.3 (2012): E156-
162.PubMed. Web. 30 Oct. 2012. 
53. Boutroy, Stephanie, Bert Van Rietbergen, Elisabeth Sornay-Rendu, Francoise Munoz, 
Mary L. Bouxsein, and Pierre D. Delmas. "Finite Element Analysis Based on In Vivo HR-
pQCT Images of the Distal Radius Is Associated With Wrist Fracture in Postmenopausal 
Women." Journal of Bone and Mineral Research 23.3 (2008): 392-99. Print. 
54. Pistoia, W. "Estimation of Distal Radius Failure Load with Micro-finite Element 
Analysis Models Based on Three-dimensional Peripheral Quantitative Computed 
Tomography Images." Bone 30.6 (2002): 842-48. Print. 
55. Harrison, N., D. O'Mahoney, P. McDonnell, and P. McHugh. "Damage and Failure of 
Trabecular Bone with Non-linear Geometry and Inhomogeneous Material 
Properties."Journal of Biomechanics 39 (2006): S417. Print. 
56. "Screening for Osteoporosis." Recommendation Statement. U.S. Preventive Services 
Task Force, July 2010. Web. 25 Oct. 2012. 
<http://www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/osteors.htm> 
57. "STL 2.0 May Replace Old, Limited File Format." STL 2.0 May Replace Old, Limited File 
Format. Rapid Publishing, LLC, 2009. Web. 20 Sept. 2012. 
<http://www.rapidtoday.com/stl-file-format.html>. 
58. "MeshLab." MeshLab. N.p., n.d. Web. 20 Sept. 2012. 
<http://meshlab.sourceforge.net/>. 
120 
 
59. Dalzell, N., S. Kaptoge, N. Morris, A. Berthier, B. Koller, L. Braak, B. Rietbergen, and J. 
Reeve. "Bone Micro-architecture and Determinants of Strength in the Radius and 
Tibia: Age-related Changes in a Population-based Study of Normal Adults Measured 
with High-resolution PQCT." Osteoporosis International 20.10 (2009): 1683-694. 
Print. 
60. Verhulp, E., B. Van Rietbergen, and R. Huiskes. "Load Distribution in the Healthy and 
Osteoporotic Human Proximal Femur during a Fall to the Side." Bone 42.1 (2008): 
30-35. Print. 
61. Gong, He, Ming Zhang, Ling Qin, and Yajun Hou. "Regional Variations in the 
Apparent and Tissue-Level Mechanical Parameters of Vertebral Trabecular Bone 
with Aging Using Micro-Finite Element Analysis." Annals of Biomedical 
Engineering 35.9 (2007): 1622-631. Print. 
62. Rhee, Yumie, June-Huyck Hur, Ye-Yeon Won, Sung-Kil Lim, Myong-Hyun Beak, Wen-
Quan Cui, Kwang-Gyoun Kim, and Young Eun Kim. "Assessment of Bone Quality 
Using Finite Element Analysis Based upon Micro-CT Images." Clinics in Orthopedic 
Surgery 1.1 (2009): 40. Print. 
63. Karim, Lamya, and Deepak Vashishth. "Role of Trabecular Microarchitecture in the 
Formation, Accumulation, and Morphology of Microdamage in Human Cancellous 
Bone." Journal of Orthopaedic Research 29.11 (2011): 1739-744. Print. 
64. Tang, S.y., and D. Vashishth. "A Non-invasive in Vitro Technique for the Three-
dimensional Quantification of Microdamage in Trabecular Bone." Bone 40.5 (2007): 
1259-264. Print. 
65. Pistoia, W., B. Van Rietbergen, E.-M. Lochmüller, C.a. Lill, F. Eckstein, and P. 
Rüegsegger. "Image-Based Micro-Finite-Element Modeling for Improved Distal 
Radius Strength Diagnosis." Journal of Clinical Densitometry 7.2 (2004): 153-60. 
Print. 
66. Pipkin, A. C. "Constraints in Linearly Elastic Materials." Journal of Elasticity 6.2 
(1976): 179-93. Print. 
67. Todhunter, I., and Karl Pearson. A History of the Theory of Elasticity and of the 
Strength of Materials, from Galilei to the Present Time. Cambridge: University, 
1886.Google Book Search. Web. 26 Oct. 2012. 
68. Rajan, Krishna. "Linear Elastic Properties of Trabecular Bone: A Cellular Solid 
Approach."Journal of Materials Science Letters 4.5 (1985): 609-11. Print. 
69. Tanabe, Yuji, and Koichi Kobayashi. "Anisotropy in the Dynamic Non-linear 
Viscoelastic Properties of Bovine Compact Bone." Journal of Materials Science: 
Materials in Medicine 5.6-7 (1994): 397-401. Print. 
70. Joo, W.K., B.I. Kim, Sung In Bae, C.S. Kim, and Jung Il Song. "Mechanical Properties 
on Nanoindentation Measurements of Osteonic Lamellae in a Human Cortical 
Bone."Key Engineering Materials 353-358 (2007): 2248-252. Print. 
71. Zamiri, A., and S. De. "Mechanical Properties of Hydroxyapatite Single Crystals from 
Nanoindentation Data." Journal of the Mechanical Behavior of Biomedical 
Materials (2010): 146-152. Print. 
72. Carnelli, D., D. Gastaldi, V. Sassi, R. Contro, C. Ortiz, and P. Vena. "A Finite Element 
Model for Direction-Dependent Mechanical Response to Nanoindentation of 
Cortical Bone Allowing for Anisotropic Post-Yield Behavior of the Tissue." Journal of 
Biomechanical Engineering 132.8 (2010): 1-10. Print. 
121 
 
73. Hambli, R., A. Bettamer, and S. Allaoui. "Finite Element Prediction of Proximal 
Femur Fracture Pattern Based on Orthotropic Behaviour Law Coupled to Quasi-
brittle Damage." Medical Engineering and Physics 34.2 (2012): 202-10. Print. 
74. Element Reference. Apr. 2009. ANSYS Release 12.0 Element Reference. 
Http://www1.ansys.com/customer/content/documentation/120/ans_elem.pdf 
75. Zysset, Philippe K., X. Edward Guo, C. Edward Hoffler, Kristin E. Moore, and Steven 
A. Goldstein. "Elastic Modulus and Hardness of Cortical and Trabecular Bone 
Lamellae Measured by Nanoindentation in the Human Femur." Journal of 
Biomechanics 32.10 (1999): 1005-012. Print. 
76. Poole, Gene. "Ansys Equation Solvers: Usage and Guidelines." 
Http://www.tynecomp.co.uk/. Tynemouth Computer Services, Apr. 2002. Web. 2 
Oct. 2012. <http://www.tynecomp.co.uk/Xansys/solver_2002.pdf>. 
77. Eddy, William F. "A New Convex Hull Algorithm for Planar Sets." ACM Transactions 
on Mathematical Software (TOMS) 3.4 (1977): 398-403. Print. 
78. Stein, E.M., X.S. Liu, T. L. Nickolas, A. Cohen, V. Thomas, D.J. McMahon, C. Zhang, 
P.T. Yin, F. Cosman, J. Nieves, X.E. Guo, and E. Shane. "Abnormal Microarchitecture 
and Reduced Stiffness at the Radius and Tibia in Postmenopausal Women with 
Fractures." Journal of Bone and Mineral Research 25.12 (2010): 2572-581. Print. 
79. Motulsky, Harvey J. The InStat Guide to Choosing and Statistical Tests. 2001. 
Software Manual. Http://www.graphpad.com/downloads/InStat3Mac.pdf. 
80. Harner, J. P., 3rd, and J. H. Wilson. "Bone Strength Statistical Distribution Functions 
for Broilers." Poultry Science 64.3 (1985): 585-87. Print. 
81. Cohen, A., D. W. Dempster, R. R. Recker, E. M. Stein, J. M. Lappe, H. Zhou, A. J. 
Wirth, G. H. Van Lenthe, T. Kohler, A. Zwahlen, R. Muller, C. J. Rosen, S. Cremers, T. 
L. Nickolas, D. J. McMahon, H. Rogers, R. B. Staron, J. LeMaster, and E. Shane. 
"Abnormal Bone Microarchitecture and Evidence of Osteoblast Dysfunction in 
Premenopausal Women with Idiopathic Osteoporosis." Journal of Clinical 
Endocrinology & Metabolism 96.10 (2011): 3095-105. Print. 
82. Follet, Helene, Stéphanie Viguet-Carrin, Brigitte Burt-Pichat, Baptiste Dépalle, 
Yohann Bala, Evelyne Gineyts, Francoise Munoz, Monique Arlot, Georges Boivin, 
Roland D. Chapurlat, Pierre D. Delmas, and Mary L. Bouxsein. "Effects of Preexisting 
Microdamage, Collagen Cross-links, Degree of Mineralization, Age, and Architecture 
on Compressive Mechanical Properties of Elderly Human Vertebral Trabecular 
Bone." Journal of Orthopaedic Research 29.4 (2010): 481-88. Print. 
83. Ghosh, Anindya. "Journal of Textile and Apparel Technology and 
Management." Spun Yarn Strength as a Function of Gauge Length and Extension 
Rate: A Critical Review4.2 (2004): 1-13. Web. 17 Oct. 2012. 
<http://www.tx.ncsu.edu/jtatm/volume4issue2/Articles/Ghosh/Ghosh_full_99_04.
pdf>. 
84. Harrigan, Timothy P., Murali Jasty, Robert W. Mann, and William H. Harris. 
"Limitations of the Continuum Assumption in Cancellous Bone." Journal of 
Biomechanics 21.4 (1988): 269-75. Print. 
85. Cohen, A., D. W. Dempster, R. Müller, X. E. Guo, T. L. Nickolas, X. S. Liu, X. H. Zhang, A. 
J. Wirth, G. H. Van Lenthe, and T. Kohler. "Assessment of Trabecular and Cortical 
Architecture and Mechanical Competence of Bone by High-resolution Peripheral 
Computed Tomography: Comparison with Transiliac Bone Biopsy." Osteoporosis 
International 21.1 (2010): 263-73. Print. 
122 
 
86. Chappard, Daniel, Nadine Retailleau-Gaborit, Erick Legrand, Michel Felix Basle, and 
Maurice Audran. "Comparison Insight Bone Measurements by Histomorphometry and 
CT." Journal of Bone and Mineral Research 20.7 (2005): 1177-184. Print. 
87. J.B. Pialat, N. Vilayphiou, S. Boutroy, P.J. Gouttenoire, E. Sornay-Rendu, R. Chapurlat, F. 
Peyrin, Local topological analysis at the distal radius by HR-pQCT: Application to in vivo 
bone microarchitecture and fracture assessment in the OFELY study, Bone, Volume 51, 
Issue 3, September 2012, Pages 362-368, ISSN 8756-3282, 
10.1016/j.bone.2012.06.008. 
88. Vilayphiou, Nicolas, Roland Chapurlat, Pierre D. Delmas, Stephanie Boutroy, Pawel 
Szulc, Bert Van Rietbergen, and Francoise Munoz. "Finite Element Analysis Performed 
on Radius and Tibia HR-pQCT Images and Fragility Fractures at All Sites in Men."Journal 
of Bone and Mineral Research 26.5 (2011): 965-73. Print. 
89. Wang, Xiang, Daniel B. Masse, Huijie Leng, Kevin P. Hess, Ryan D. Ross, Ryan K. Roeder, 
and Glen L. Niebur. "Detection of Trabecular Bone Microdamage by Micro-computed 
Tomography." Journal of Biomechanics 40.15 (2007): 3397-403. Print. 
90. D L Kopperdahl and Tony M. Keaveny., "Yield strain behavior of trabecular 
   bone” , J. Biomechanics,31,601-608, (1998). 
91. Hernandez, J. D., K. Wesseling, R. Pereira, B. Gales, R. Harrison, and I. B. Salusky. 
"Technical Approach to Iliac Crest Biopsy." Clinical Journal of the American Society of 
Nephrology 3.Supplement 3 (2008): S164-169. Print. 
92. Keaveny, Tony M., Robert E. Borchers, Lorna J. Gibson, and Wilson C. Hayes. 
"Trabecular Bone Modulus and Strength Can Depend on Specimen Geometry." Journal 
of Biomechanics 26.8 (1993): 991-1000. Print. 
93. Noel M. Harrison, Pat F. McDonnell, Denis C. O’Mahoney, Oran D. Kennedy, Fergal J. 
O’Brien, Peter E. McHugh, Heterogeneous linear elastic trabecular bone modelling 
using micro-CT attenuation data and experimentally measured heterogeneous tissue 
properties, Journal of Biomechanics, Volume 41, Issue 11, 7 August 2008, Pages 2589-
2596, ISSN 0021-9290, 10.1016/j.jbiomech.2008.05.014. 
94. Tsafnat, Naomi, and Stephen Wroe. "An Experimentally Validated Micromechanical 
Model of a Rat Vertebra under Compressive Loading." Journal of Anatomy (2010): 40-
46. Print. 
95. Vico, L., Zouch, M., Amirouche, A., Frère, D., Laroche, N., Koller, B., Laib, A., Thomas, T. 
and Alexandre, C. (2008), High-Resolution pQCT Analysis at the Distal Radius and Tibia 
Discriminates Patients With Recent Wrist and Femoral Neck Fractures. J Bone Miner 
Res, 23: 1741–1750. doi: 10.1359/jbmr.080704 
96. Ulrich, D., van Rietbergen, B., Weinans, H., and Rüegsegger, P., (1998), Finite Element 
Analysis of trabecular bone structure: a comparison of image-based meshing 
techniques, J. Biomech., 31, 1187-1192. 
97. Grant Bevill, Senthil K. Eswaran, Farhad Farahmand, Tony M. Keaveny., “The influence 
of boundary conditions and loading mode on high-resolution finite element-computed 
trabecular tissue properties” , Bone,44,573-578, (2009). 
123 
 
98. Gomberg, B., P. Saha, and F. Wehrli. "Method for Cortical Bone Structural Analysis 
From Magnetic Resonance Images." Academic Radiology 12.10 (2005): 1320-332. 
Print. 
99. Adachi, T., M. Tanaka, and Y. Tomita. "Uniform Stress State in Bone Structure with 
Residual Stress." Journal of Biomechanical Engineering 120.3 (1998): 342. Print. 
100. Yamada, Satoshi, Shigeru Tadano, and Kazuhiro Fujisaki. "Residual Stress Distribution 
in Rabbit Limb Bones." Journal of Biomechanics 44.7 (2011): 1285-290. Print. 
101. Bevill, Grant, and Tony M. Keaveny. "Trabecular Bone Strength Predictions Using Finite 
Element Analysis of Micro-scale Images at Limited Spatial Resolution." Bone 44.4 
(2009): 579-84. Print. 
102. J.H Keyak, Improved prediction of proximal femoral fracture load using nonlinear finite 
element models, Medical Engineering &amp; Physics, Volume 23, Issue 3, April 2001, 
Pages 165-173, ISSN 1350-4533, 10.1016/S1350-4533(01)00045-5. 
103. Macneil, J., and S. Boyd. "Bone Strength at the Distal Radius Can Be Estimated from 
High-resolution Peripheral Quantitative Computed Tomography and the Finite Element 
Method." Bone 42.6 (2008): 1203-213. Print. 
104. Norman, Jonathan, Joe G. Shapter, Ken Short, Lachlan J. Smith, and Nicola L. Fazzalari. 
"Micromechanical Properties of Human Trabecular Bone: A Hierarchical Investigation 
Using Nanoindentation." Journal of Biomedical Materials Research 87A.1 (2007): 196-
202. Print. 
105. Rho, Jae-Young, Marcel Roy, and George M. Pharr. "Comments on ‘Elastic Modulus 
and Hardness of Cortical and Trabecular Bone Lamellae Measured by Nanoindentation 
in the Human Femur’." Journal of Biomechanics 33.10 (2000): 1335. Print. 
106. Viguet-Carrin, S., P. Garnero, and P. D. Delmas. "The Role of Collagen in Bone 
Strength." Osteoporosis International 17.3 (2006): 319-36. Print. 
107. O'Mahony, Aisling M., John L. Williams, and Paulette Spencer. "Anisotropic Elasticity of 
Cortical and Cancellous Bone in the Posterior Mandible Increases Peri-implant Stress 
and Strain under Oblique Loading." Clinical Oral Implants Research 12.6 (2001): 648-
57. Print. 
108. Jesper Kabel, Bert van Rietbergen, Michel Dalstra, Anders Odgaard, Rik Huiskes, The 
role of an effective isotropic tissue modulus in the elastic properties of cancellous 
bone, Journal of Biomechanics, Volume 32, Issue 7, July 1999, Pages 673-680, ISSN 
0021-9290, 10.1016/S0021-9290(99)00045-7. 
109. Guo, Xiang-Dong E., Thomas A. McMahon, Tony M. Keaveny, Wilson C. Hayes, and 
Lorna J. Gibson. "Finite Element Modeling of Damage Accumulation in Trabecular Bone 
under Cyclic Loading." Journal of Biomechanics 27.2 (1994): 145-55. Print. 
  
124 
 
VITA 
• Lucas Tyler Wilkerson 
 
• Degrees Awarded: 
o Bachelors of Science in Mechanical Engineering 
 University of Kentucky 
 May 2010 
• Professional Positions: 
o Aeronautical Engineer 
 Belcan Corporation: Advanced Engineering and Technology Division 
 May 2010 – present 
o Mechanical Engineering CO-OP 
 Lexmark International, Inc.: Color Fuser Development 
  May 2008 – May 2010 
• Honors and Awards 
o University of Kentucky Multi-Year Fellowship  
o University of Kentucky Presidential Scholarship 
o Outstanding Mechanical Engineering Sophomore Award  
o John A. Brittain Scholarship 
o ASME Bluegrass Section Outstanding Scholar Award: Spring 2009  
